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ABSTRACT 
 Novel and potent ligands to the serotonin7 (5-HT7) receptor have been synthesized.  The 
synthesized compounds include a set of substituted pyrimidines which show high affinity to the 5-HT7 
receptor, synthesized by previously described methods [1,2] in high yield.  Comparing the affinities of 
substituted pyrimidines to previously calculated models [3,4] yielded new hypotheses about the nature 
of interaction between the pyrimidine ligands and the 5-HT7 binding site.  Several new series of 
compounds were synthesized by various methods to validate these hypotheses, including a conjugate 
addition to vinylpyrimidines [5].  These compounds include benzofurans, oximes, hydrazones, as well as 
a group of substituted piperazines.  All series of compounds show affinity to the 5-HT7 receptor 
 
 
comparable to previously synthesized 5-HT7 ligands.  Several of the synthesized ligands show affinity 
which exceeds that of currently available ligands. 
The synthesized compounds were evaluated quantitatively by calculating a three-dimensional 
quantitative structure-affinity relationship (3D-QSAR) for the 5-HT7 receptor.  Evaluation of the 
calculated model validated qualitative assumptions about the data set as well as described regions of 
interaction in greater detail than previously available.  These observations give further insight on the 
nature of ligand-binding site interactions with highly potent ligands such as 4-(3-furyl)-2-(N-
methylpiperazino)pyrimidine which will lead to more potent 5-HT7 receptor ligands.  Additionally, a 
model was calculated for affinity to the 5-HT2a receptor.  Comparing this model to that calculated for 
affinity to the 5-HT7 receptor identified two regions which may be exploited in future sets of ligands to 
increase selectivity to the 5HT7 receptor. 
INDEX WORDS: Serotonin, 5-HT, Depression, Schizophrenia, Pyrimidine, 1-4 Addition, 3D-QSAR, 
Molecular modeling, 5-HT7 receptor, 5-HT7 ligands, 5-HT1a, 5-HT2a, Pharmacophore 
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1 INTRODUCTION 
 
1.1 The characterization of serotonin 
Research on serotonin began with its discovery [6] which is credited to Erspamer [7] whose work 
with smooth muscle contraction led him to observe an amine in cells of the gut.  Erspamer observed 
that this compound was responsible for muscle contraction seen in his experiments and named it 
enteramine (enteric1 amine) without full characterization [8].  In separate 
research, serotonin was isolated from blood [9] and named such for its 
properties as a vasoconstrictor2.     Rapport succeeded in the 
crystallization and characterization of serotonin, defining the structure as 
5-hydroxytryptamine and identical to the enteramine described by Erspamer [10,11].  Two years later, 
serotonin was synthesized and made commercially available, and research on serotonin grew rapidly. 
Several reports followed which described serotonin prevalent throughout the periphery. The presence 
of serotonin in the central nervous system3 (CNS) [12] quickly led to its identification as a 
neurotransmitter [13].  These studies are the foundation for the current understanding of the 
serotonergic system.  This understanding has been advanced significantly, but there remains much to be 
desired.  This research aims to further the knowledge of the serotonergic system by synthesizing novel 
ligands to be used in physiological4 studies.  Research using these compounds promises to extend the 
knowledge of the serotonergic system and help to identify therapeutic uses, such as antidepressants. 
 
                                                          
1
 enteric – pertaining to the intestines 
2
 vasoconstrictor – a compound which causes the blood vessels to contract 
3
 central nervous system – a broad characterization of the structures which allow for communication with the 
periphery and the environment and includes all of the brain and spinal cord 
4
 physiological – referring to the biological purpose of a receptor as it relates to the process it affects within the 
body 
OH
N
H
NH2
Serotonin 
(5-hydroxytryptamine, 5-HT) 
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1.2 The serotonergic system 
 
The prevalence of serotonin within the central 
nervous system (CNS) provides a biological 
pathway for controlling a diverse set of 
physiological functions.  Understanding the 
biological means for the release and reuptake of 
serotonin illuminates the reasoning for current 
drug strategies.  Serotonin is a neurotransmitter 
and takes action upon serotonin receptors within 
the CNS.  The concentration of serotonin at the 
receptor site is governed by a complex network of 
cells and proteins.  It is the control over this 
concentration which is desired and the biological 
routes for doing so are described.  It is prudent to note that the whole of serotonin producing and 
binding cells is often called the serotonergic system.  This is somewhat misleading however, as 
serotonergic neurons in the body do not act cohesively, but act largely independent of one another [14].  
This flexibility allows for serotonergic pathways to simultaneously illicit a multitude of distinct 
physiological responses.   
 
Each serotonergic neuron is linked to another neuron capable of detecting serotonin through 
receptors on its surface.  The release of serotonin is controlled by the firing rate of the neuron.  The 
serotonin diffuses into nearby 5-HT receptor sites.  This binding event causes a conformational shift of 
3 
 
 
 
the receptor and results in signal transduction5.  Controlling this binding event is a major step toward 
gaining control over the end result of 5-HT receptors. 
Serotonin is synthesized biologically by a short pathway beginning with the amino acid L-tryptophan, 
shown in Figure 1-1.  Two enzymes6 carry out this biosynthesis and it is the first of these two, 
tryptophan hydroxylase (TPH) which is the rate limiting step [15].  Therefore, the second enzyme 
involved in the biosynthesis, 5-HT decarboxylase, is a less attractive therapeutic target.  The level of 
research on the inhibition of this enzyme reflects this observation.  TPH introduces a hydroxyl group on 
the aromatic region of the amino acid and exists in two different isoforms, TPH1 and TPH2.  These 
different forms exist almost exclusively in isolation from each other with TPH1 acting in the periphery 
while TPH2 acts in neuronal7 cells.  Inhibition of TPH1 has the potential to allow control of serotonin 
levels in the blood and gastrointestinal8 tract.  This may prove to be therapeutically useful in 
hypertension [16] and gastrointestinal disorders such as irritable bowel syndrome [17].  Inhibition of 
TPH2 has been shown to reduce brain serotonin levels [18].  However, therapeutic use for TPH2 
inhibitors9 is limited, due to the global nature of the serotonin depression throughout the CNS.  This 
decreased level of serotonin likely causes many unwanted side effects.  Most therapeutic targets in the 
CNS are aimed to increase synaptic serotonin levels.  Inhibiting TPH2 would have the opposite effect, 
making even the targeted effect opposite of that desired.  Thus, the selective inhibition of TPH1 to alter 
serotonin levels in the blood and gastrointestinal tract is likely the only viable therapeutic strategy for 
these biological pathways [19].  
                                                          
5
 signal transduction – the process of relaying an extracellular signal, such as increased concentration of a 
neurotransmitter, into intracellular changes 
6
 enzyme – a protein which catalyzes a chemical reaction 
7
 neuronal – pertaining to the cells (neurons) which regulate the release and reuptake of neurotransmitters for the 
purpose of signal transmission between nerve cells 
8
 gastrointestinal – pertaining to the entire system which is used to extract nutrients from ingested food, beginning 
at the oral cavity and ending at the anus 
9
 inhibitors – a compound which the activity of a specific protein upon binding 
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Serotonergic drugs have been focused on artificially increasing serotonin levels in vivo.  This has 
been accomplished most successfully by blocking the clearance of serotonin.  This clearance occurs by 
two different routes, reuptake into a neuronal cell or metabolism.  Inhibiting the enzymes responsible 
for serotonin clearance has resulted in several commercially successful drugs.  The main protein 
responsible for the reuptake of serotonin is the serotonin transporter (SERT).  Inhibition of this 
transporter has led to the most commercially successful products of serotonin research [20].  By 
blocking the reuptake into the neuronal cells, serotonin levels are artificially raised.  This has led to use 
as anti-depressants [21] and for other mood related conditions.  Marketed as serotonin specific 
reuptake inhibitors (SSRIs), these compounds amplify the amount of serotonin throughout the CNS.   
This results in many side effects due to poorly defined physiological profiles.  There is evidence to 
support an additional transporter that plays a significant part in serotonin reuptake, the plasma 
membrane monoamine transporter (PMAT).  This protein does not transport serotonin as efficiently as 
SERT, but does so with a much greater capacity.  It is therefore possible that PMAT plays a significant 
role in serotonin reuptake [22].  The efficiency of current SSRIs may be improved by analyzing their 
effect on PMAT and optimizing the ligands for dual inhibition to these transporters. 
Much like blocking the reuptake of serotonin, inhibiting monoamine oxidase (MAO) effectively 
raises global serotonin levels by blocking its metabolism [23].  Drugs targeting MAO represent another 
commercially successful class of compounds.  As with the TPH enzyme, MAO enzymes also exist in two 
forms, MAO-A and MAO-B, both of which are present in the CNS.  MAO-A preferentially metabolizes 
serotonin into 5-hydroxyindoleacetic acid along with other monoamines.  Since the end result of MAOIs 
is much the same as SSRIs, they are susceptible to the same faults such as multiple side effects due to 
poor physiological profiling.  MAOIs have the added difficulty of increasing the concentration of other 
monoamine neurotransmitters as well, as they are not specific to serotonin. 
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A seemingly more advantageous approach to controlling the serotonin signal is to design selective 
ligands for the receptor subtype responsible for mediating a specific function [24].  The ability to discern 
between different types of serotonin receptors adds another level of selectivity10 to the SSRI class of 
compounds.  This may ultimately allow for the serotonin signal to be more discretely directed toward 
the functions of a particular serotonin receptor, as opposed to universally altering the level of post-
synaptic serotonin, as is the case with SSRIs and MAOIs.  Ideally, the administration of serotonin 
receptor ligands selectively activates or inhibits the functions specific to that receptor.  The 
development of such selective ligands offers an improvement over current drug treatments, although 
the functions regulated by each subtype are not singular and may still produce unwanted side effects.    
Existing serotonin ligands and their therapeutic uses and relevance is discussed in detail.‡ 
 
1.3 Therapeutic relevance 
 
Manipulation of the serotonergic system has been established as a valid method for regulating 
biological functions.  The prevalence of serotonin throughout the brain and body has been well 
documented [25].  It has been shown that serotonin plays a major role in several vital functions which 
implicate the neurotransmitter in many biological processes.  Each of these biological processes 
represents an opportunity for therapeutic use.  Table 1-1 below shows the most accepted processes 
which serotonin is thought to regulate to some degree.  The regulation of visceral motor response is 
most noted in the gut, where serotonin is responsible for initiating the migrating contractions of the 
bowel [26].  The electrical impulses of serotonergic neurons have also been shown to be in step with the 
                                                          
10
 selectivity – describes a ligand which binds to only one (or a limited amount) of receptors; in this case, 5-HT 
receptor subtypes and other monoamine receptors 
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circadian pacemaker11, which regulates sleep-wake cycle among other things.  It has also been shown 
that differing levels of serotonergic activity in a developing brain can significantly affect the function of 
the adult.  This also includes conditions related to sexual behavior [27], mood [28], regulation of the 
body standards (temperature [29], blood pH [30], blood pressure [31], appetite[32]), learning and 
memory [33], gastrointestinal disorders [34], perception of pain [35], and neurological disorders [36-40].  
The involvement of serotonin in regulation of behavioral aspects is more difficult to describe, largely due 
to the lack of precision in the definition of these disorders.  Altered serotonin levels and expression of 
serotonin receptors, transporters, and neurons in the brain have been associated with abnormal 
behaviors.  The regulation of behavior has been the most successful area of serotonin research, yielding 
many commercially successful drugs aimed at depression and schizophrenia.  However, the action of 
these drugs is not sufficiently understood. The synthesis of ligands in order to better understand these 
processes is a major focus of this research.    
                                                          
11
 circadian pacemaker – refers to the structures which maintain daily rhythms such as feeding and sleeping 
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Table 1-1.  Serotonergic pathways have been implicated in the regulation of the listed conditions. 
 
 
1.4 The need for more selective serotonin receptor ligands 
 
A common theme present in many physiological studies on 5-HT receptors used to produce the 
functional theories is the incomplete nature of the studies due to lack of sufficiently potent and selective 
ligands [27, 34, 43, 53].  The need for selective ligands comes from the diversity of serotonin receptor 
subtypes.  There are fourteen subtypes of 5-HT receptors characterized to date, all binding the same 
ligand.  The selective interaction of ligands with individual subtypes allows for research on their distinct 
                                                          
12
 forebrain structures – refers to structures implicated in higher order thought processes 
13
 raphe nuclei – portion of the brain which houses an overwhelming majority of serotonergic neurons; near the 
brainstem 
14
 dyspepsia – a loosely defined stomach ailment similar to an upset stomach or indigestion 
Processes which may be 
regulated by 5-HT 
Conditions arising from regulated processes 
of therapeutic relevance 
Proposed method of 
serotonergic involvement 
   
mood anxiety [41,42], conduct disorders (ADD, OCD, 
etc.) [43], depression [44], locomotion/energy 
balance [45] 
serotonergic innervations to 
forebrain structures12 
body standards blood pressure [31], internal temperature 
[29], body fluid homeostasis [30], 
appetite/obesity [32], sleep disorders [46] 
serotonergic neurons in the 
hypothalamus and brainstem 
projections from raphe nuclei13 
learning and memory schizophrenia [39], Alzheimer’s disease [40] ascending serotonergic 
neurons into the frontal cortex, 
hippocampus and other 
brainstem projections from the 
raphe nuclei 
perception of pain nociception [35], migraine [47, 48] descending serotonergic pain 
inhibitory system 
neurological disorders Parkinson’s disease [37], epilepsy [38] inhibition of dopamine release 
and methods of cognition 
gastrointestinal disorders dyspepsia14 [49], irritable bowel syndrome 
[50], heartburn [51], gastroparesis [52] 
gastrointestinal motility, fluid 
secretion in the bowel 
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physiological properties.  While the challenge to synthesize the ligands which are selective to each 
subtype has been daunting, the aim is to achieve a greater level of control over the broad spectrum of 
functions.  Complicating the issue further is the need for selectivity not just over other serotonin 
receptor subtypes, but other similar neurotransmitter receptors, such as noradrenergic, cholinergic, and 
dopaminergic receptors [3].  This research has produced effective ligands for some of the receptor 
subtypes [34], which has led to important discoveries regarding those subtypes.  There are several 
receptor subtypes for which improvements on the currently available ligands are needed.  Ongoing 
efforts to this end have produced many novel classes of ligands [54]  and several binding studies to 
elucidate the requirements for the desired selectivity and potency [3].  The evolution of these ligands 
has helped clarify the physiological profile for serotonergic receptors and the therapeutic value of 5-HT 
receptor ligands. 
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2 LITERATURE REVIEW 
2.1 Serotonin receptor subtypes and other related G-protein coupled receptors (GPCR) 
 
As mentioned, synthesizing ligands which interact at the serotonin receptors allows the greatest 
control over serotonergic function.  This is due to the diversity of serotonin receptor subtypes which are 
expressed throughout the CNS.  Each of the fourteen 5-HT receptor subtypes exhibits a unique 
pharmacology and expression in the body.  These include 7 groups of receptor subtypes: 5-HT1 (5-HT1a, 
5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F) 5-HT2 (5-HT2a, 5-HT2B, 5-HT2C), 5-HT3, 5-HT4, 5-HT5A (5-HT5B found in rats), 
5-HT6, and 5-HT7.  All 5-HT receptors (except for the 5-HT3 receptor, which is a ligand gated ion channel) 
belong to a large family of receptors known as G-protein15 coupled receptors (GPCRs).  Therefore, 
affinity to a single 5-HT receptor subtype must be evaluated against all other subtypes as well as other 
monoaminergic receptors, in order to determine its selectivity.  These receptors are characterized by a 
seven transmembrane, alpha-helical structure which enables their function as membrane bound 
receptors.  This general structure is shown by the model in Figure 2-1 (page 11).  When a receptor ligand 
binds to the extracellular region of the receptor, a conformational shift within the receptor takes place.  
This conformational change in the receptor has been proposed to be very similar for all GPCRs and 
especially among 5-HT receptors [55].  It is this shift that activates the intracellular region of the 
receptor and results in the signaling event.  The three-dimensional structure of these proteins has been 
difficult to obtain experimentally due to many factors including difficulties with crystallizing the 
membrane protein [56].  The crystallization of the GPCR bovine rhodopsin [57], allowed for structural 
comparisons to other GPCRs.  Much of the information about the binding site of 5-HT receptors and the 
conformational changes that take place upon binding is inferred from this crystal structure.  
                                                          
15
 G-protein – a guanidine binding protein; commonly seen with G-protein coupled receptors and use alternate 
phosphoryllation states of guanidine as a switch in signal transduction 
10 
 
 
 
Comparisons between this receptor and others must take some liberties in their assumptions, but draw 
from the fact that while most 5-HT receptors share a sequence homology16 of about 35%, there are 
conserved regions which are practically identical.  These regions are thought to be involved in the 
binding event of most GPCRs, including the thirteen 5-HT receptor subtypes [58].  
In addition to the complexity contained within the serotonergic family of receptors, other receptors 
and ion channels can bind 5-HT receptor ligands.  Adrenergic receptors are a class of monoamine 
receptors which exhibit similarities in their physiological profile to some 5-HT receptors.  In fact, some 
ligands that were thought to be selective for certain 5-HT receptor subtypes have shown high affinity to 
the adrenergic α2 receptor [59].  Similarly, dopaminergic receptors are often conflated with serotonergic 
receptors in their functions.  Selectivity for dopaminergic receptors with respect to 5-HT receptors has 
been shown to be a significant concern addressed in recent research [60].  It is therefore necessary to be 
mindful of this relationship when designing new selective 5-HT receptor ligands.  Other receptors which 
have shown some similarity to 5-HT receptor ligands include ion channels, monoamine (GABA, 
norepinephrine, etc.) receptors and transporters [61].  This apparent complexity is somewhat simplified 
in practice by focusing on achieving selectivity over the most similar receptor subtypes and 
subsequently testing the affinity for a wide range of receptors.  This approach has been shown to be 
reasonable, resulting in the synthesis of increasingly selective 5-HT receptor ligands in recent years. 
2.2 The 5-HT7 receptor 
 Being the most recently discovered 5-HT receptor subtype [62], the 5-HT7 receptor has become 
increasingly distinguished from other 5-HT receptor subtypes according to its locations, mechanism of 
signal transduction, primary sequence17 and higher order structure18.  The 5-HT7 receptor was initially 
                                                          
16
 sequence homology – a measure of the similarity between the sequence of residues in two related proteins 
17
 primary sequence – the order of amino acid residues in a protein 
11 
 
 
 
characterized as a 5-HT1 receptor subtype based on its affinity to certain ligands thought to be selective 
for 5-HT1 receptors.  Although later studies on its signal transduction method revealed that this receptor 
was significantly different [63], the similarity between these subtypes was an early indicator that 
selectivity with regard to these subtypes would be problematic.  This finding also somewhat invalidated 
previous research on the functions of existing subtypes which used ligands shown not to be selective.  
As a result, the newly discovered 5-HT7 receptor was implicated in several conditions thought to be 
regulated by 5-HT1 receptor subtypes.  Its full potential as a therapeutic target remains unclear due to 
the inability to separate its functions from those of other similar receptor subtypes.   
In addition to comparisons with other receptors, comparisons with splice variants19 of the 5-HT7 
receptor have been made [64].  There are four splice variants of the mammalian 5-HT7 receptor, only 
three of which have been found in humans.  These variants of the receptor are thought to differ only 
near the intracellular carboxy terminal, meaning that selectively binding these isoforms is not practical 
[65].  These differences may affect the overall action of the receptor, but likely only modify the signal 
transduction mechanism after the binding event concerning the coupling of the intracellular G-protein.  
Therefore, the effects of differences between these variants go largely overlooked in the attempt to 
produce selective binding agents to the receptor.  The validity of this approach is established as more 
becomes known about the structure of the 5-HT7 receptor and its splice variants. 
 
 
 
                                                                                                                                                                                           
18
 higher order (protein) structure – the complex three-dimensional folding patterns of proteins which form 
common structures, such as alpha helices 
19
 splice variants – refers to the proteins which are encoded from the same DNA sequence, yet have different 
primary sequences; in the case of the 5-HT7 receptor, splice variants exist in which the protein sequence is 
truncated 
12 
 
 
 
2.2.1 Biological expression and functions of 5-HT7 receptors 
While there is not a perfect correlation between location and function, observing the primary 
locations of the 5-HT7 receptor gives some insight to the receptor’s role and possible therapeutic 
relevance.  Expression of the 5-HT7 receptor in several different species has been thoroughly examined 
and reviewed [66].  Although the locations and concentration of the 5-HT7 receptor vary largely from 
species to species and according to the methods used in each study, there is still enough evidence in the 
current literature to make some meaningful assumptions about the presence of this receptor in certain 
organs.  These assumptions lead to theories and research about the specific physiology of the 5-HT7 
receptor. 
The precursor for the 5-HT7 protein, 5-HT7 mRNA, has been studied through molecular biology 
approaches [66].  These methods have found that mRNA for the 5-HT7 receptor is mainly found in the 
CNS; more specifically in the hypothalamus, thalamus and hippocampus [66].  This supports the idea 
that the 5-HT7 receptor is most concentrated in these brain structures.  It may also be noted that this 
assumption falls in accord with the long-standing implication of 5-HT7 receptors in processes believed to 
be regulated by these structures, such as cognition and higher-order brain function.  In additional 
studies on the distribution of the receptor, the correlation between mRNA and receptor concentration is 
supported.  The methods of determination are more direct as they measure the concentration of the 
receptor directly, but also have innate flaws relating to the binding selectivity of ligands to the 5-HT7 
receptor.  Several studies [67] have shown the distribution of the receptor to be consistent with that of 
the mRNA.  It is also worth mentioning that while the highest concentration of 5-HT7 receptors is found 
within the CNS, this receptor is also involved in functions throughout the periphery.  This involvement is 
evidenced by its widespread presence in smooth muscle cells.  The 5-HT7 receptor has thus become 
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included in the possible treatment of conditions related to the relaxation of blood vessels such as 
migraine [68] and irritable bowel syndrome [69]. 
As more research is conducted on the functions of the 5-HT7 receptor, it has become reasonable to 
assume that these receptors have a significant and unique role in many essential brain functions.  
However, as this receptor becomes increasingly implicated in brain function, it may be important to 
note the correlation with ligand availability and this observed increase.  There are several processes 
which are now believed to be mediated specifically by 5-HT1a and 5-HT7 receptors.  It is possible that this 
correlation is observed due to availability of ligands which selectively bind only these receptors.  In 
reality, these functions may be mediated by a much more complex response from several serotonin 
receptor subtypes.  Research with novel selective ligands will help to advance this research. 
2.2.2 Mechanism of signal transduction 
The mechanism of action of the 5-HT7 receptor follows that of the general mechanism of the 
superfamily of receptors to which it belongs (see review [67] and references therein), known as G-
protein coupled receptors (GPCR).  These receptors transmit their signal through an association with an 
intracellular protein (G-protein).  This association initializes a signal cascade when the receptor is bound 
with an agonist20.  In summary, activation of the 5-HT7 receptor causes an increase in intracellular cyclic 
AMP (cAMP) [70].  This increase can then influence several different signaling cascades depending on 
the particular cell type in which the receptor is expressed.  These signaling pathways provide more clues 
to the function and importance of the 5-HT7 receptors.  Observing the end results of these pathways 
allows insight into what the end result of receptor activation may affect.  As an example, it has been 
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 agonist – a compound which upon binding to a receptor causes activity identical to when the receptor is bound 
with the natural ligand 
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reported that the 5-HT7 receptor can activate a kinase
21 (ERK) in hippocampal neurons [71], further 
supporting the receptor’s role in mood regulation [67].  
It may also be the case that the 5-HT7 receptor does not operate on the strict axis of activation and 
inactivation put forward by the ternary complex model22.  Recent research shows that many GPCRs, 
including the 5-HT2a receptor, may operate according to the agonist-trafficking theory [72].  This theory 
postulates that different agonists may cause different structural changes in the receptor, and thus, 
affect different signaling cascades [73].  This has been proposed to be the mechanism by which 
hallucinogens such as LSD have a profoundly differing effect when bound to the 5-HT2a receptor than 
other agonists [74].  If this is indeed the case for the 5-HT7 receptor, the physiological profile of this 
receptor is only made more complex. Further studies on the structure of agonist bound receptors are 
needed to make conclusions on how this information modifies the attractiveness of GPCRs as a 
therapeutic target. 
2.2.3 Conformational changes upon binding 
Research has recently provided detailed pharmacophores23 of the binding site from X-ray 
crystallography and molecular modeling methods.  Due to the fact that GPCRs are transmembrane 
proteins, they have proven difficult to crystallize [56].  While some GPCRs have been crystallized in their 
activated and inactivated states, structural data from X-ray crystallographic techniques is limited. 
However, this information about similar GPCRs along with molecular modeling research [75,76] has 
produced a reasonable understanding for structural changes which take place after the ligand binds to 
                                                          
21
 kinase – an enzyme which modulates the transfer of a phosphate group between two structures 
22
 ternary complex model – a model for ligand binding which assumes a direct relationship between the 
dissociation constants of two ligands with respect to a receptor;  used to determine the affinity of novel 
compounds to a receptor 
23
 pharmacophore – a map of regions which describe the necessary characteristics for binding a receptor;  a 
complete pharmacophore will include all necessary regions for binding and describe the nature of those 
interactions 
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GPCRs.  As before, these observations are likely 
common to all GPCRs, including the 5-HT7 
receptor and other serotonin receptor 
subtypes.  More information about how these 
proteins realign their structures upon binding 
gives further insight into the design of novel 5-
HT receptor agents.  The difficulties in 
selectively binding 5-HT receptors due to their 
high similarity have been discussed.  Modeling 
calculations take advantage of these similarities 
to estimate a binding site structure.  Because the GPCR family is highly conserved in certain areas, 
including the binding site, the overall structural changes that take place during binding an agonist are 
assumed to be similar for all 5-HT receptors.  While the resolution resulting from these methods may 
not be sufficient for describing precise spatial differences between 5-HT receptor subtypes, it is assumed 
to be adequate for studying the binding mechanism.  Researchers have taken advantage of this using 
several different structures and calculated models to make comparisons.  This information has been 
reviewed in detail [55] and is summarized below. 
The transmembrane region of the 5-HT7 receptor consists of seven alpha-helical domains (TM 1-7, 
Figure 2-1) which serve as the core structural element of all GPCRs.  These alpha helices alter their 
alignment with each other after binding an agonist.  This conformational shift greatly alters the overall 
structure of the protein.  This realignment causes the G-protein to exist in an activated state and is the 
basis of the signal transduction ability of the protein.  As labeled by Nichols[8] [3], TM 1-4 serve as the 
rigid core of the receptor, while TM 5-7 are thought to be responsible for inducing structural changes in 
the intracellular region.  The intracellular loops connecting the TM regions (IL 1-3) are proposed to 
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couple to the G-protein, and therefore, changes in the position of these loops affect receptor activation.  
The specific cascade of conformational changes which takes places is largely hypothetical and extremely 
complex, but there are a few steps in this process which are generally accepted mechanisms of GPCRs.  
The mechanism is thought to involve the movement of TM 3, 6 and 7.  These regions are set into motion 
as serotonin binds to the conserved Asp 3.32 residue (nomenclature as in [55], Res 3.50 is the most 
conserved residue of TM 3).  As the protonated amine of serotonin forms a salt bridge with Asp 3.32, the 
ligand is further positioned by interactions between the hydroxyl group and Ser 5.43.  This positioning 
step has been proposed to be where binding selectivity is conferred.  After these groups become 
associated with each other, several interactions which serve to stabilize the receptor in its inactive state 
are disrupted by concerted movements within the core of the receptor.  These interactions have been 
summarized in great detail [55] and are discussed in the following section as they correspond with 
pharmacophoric regions proposed by several different groups.  The combined effect of these 
destabilizing interactions causes TM 6 to move away from TM 3, causing a key interaction between Glu 
6.30 and Arg 3.50 to dissociate.  These residues are stabilized when dissociated from each other, 
minimizing the strain on the activated receptor caused by the separation of these oppositely charged 
residues.  This triggers movement of TM 5, disrupting interactions with IL 3 that keep it closely tethered 
to the receptor while inactive.  Once IL 3 is allowed to move away from the receptor, the G-protein takes 
its activated heterotrimeric form and the signal transduction circuit is completed. 
The actions of the binding mechanism can be related to pharmacophore hypotheses projecting the 
need for certain functional groups in specific regions in the binding site.  These vital binding site 
requirements all seem to actively participate in receptor activation.  In the proposed pharmacophore 
hypothesis there are five possible ligand interactions with the binding site.   These include a protonated 
amine (PA), hydrogen bond acceptors (HBA), and hydrophobic/aromatic regions (HYD/AR).  These 
interactions between the binding site regions and several different classes of ligands are illustrated well 
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by a recent pharmacophore model by Kolczkowski [77].  These studies were performed on calculated 
models of the receptor, so they are not useful for high resolution considerations.  They do, however, 
serve the purpose of illustrating possible interactions within the binding site.  The next section details 
how interactions between these residues may be advantageous for design of novel selective ligands of 
the 5-HT7 receptor. 
2.2.4 Pharmacophores of 5-HT1a, 5-HT2a, and 5- HT7 receptors 
The necessary binding site interactions between ligands and 5-HT receptors were mentioned in the 
previous section.  It is prudent to discuss calculated pharmacophores which describe these interactions 
visually, and in greater detail.  These models have been calculated from several groups of high affinity 
ligands, with differing degrees of selectivity to the 5-HT7 receptor.  It is a major goal of this research to 
improve on the selectivity and affinity of ligands to serotonin receptor subtypes, namely the 5-HT7 
receptor.  In order to derive more detailed information about the differences between the receptor 
subtypes and how to exploit those differences, it is useful to calculate a pharmacophore.  These studies 
compare high affinity ligands and use their structural similarities to make quantitative observations 
about the binding interactions between the ligand and the receptor.  Although these methods have 
drawbacks, this research has continually improved upon pharmacophores for selectively binding to the 
5-HT7 receptor.  Calculation of pharmacophores and subsequent optimization of ligands has resulted in 
thousands of novel 5-HT7 receptor ligands.  A summary of the evolution of the pharmacophore for the 5-
HT7 receptor follows.  
The development of a pharmacophore hypothesis for the 5-HT7 receptor began with simple 
observations about the database of 5-HT7 receptor ligands and their affinity.  It was initially assumed 
from analysis of a small set of benzindoles that a central aromatic group must be present for affinity 
[78].  Although a somewhat narrow prediction, this observation has contributed to the current definition 
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of the 5-HT7 receptor 
pharmacophore.  As the 
database of ligands grows, the 
pharmacophore calculations 
become more detailed.  The 
first significant pharmacophore 
hypothesis to include a 
quantitative projection of 
ligand functional groups was published by Lopez-Rodriguez, et al [79].  Their proposed pharmacophore 
(similar to Figure 2-3) predicted antagonism of the 5-HT7 receptor by analyzing 30 previously synthesized 
compounds.  These calculations described the initial scaffold for antagonists24 of the 5-HT7 receptor.  As 
more ligands have been synthesized, the optimal spatial arrangement of these interactions has become 
more precise. 
A subsequent study on the 5-HT7 receptor [80] yielded information about similarities between 5-HT7 
and 5-HT1a receptors (Figure 2-2).  In doing so, a pharmacophore was calculated for selectivity to 5-HT7 
relative to 5-HT1a receptors.  Increased detail in the field contours and regions show that the 
hydrophobic group adjacent to the positively charged amine may play a crucial role in receptor 
selectivity.  There is evidence of a hydrophobic interaction (large green contour) as well as a region 
corresponding to a protonated amine.  Also present are electrostatic favored and disfavored regions 
within the large green contour.  This presence of these regions foreshadows a possible hydrogen 
bonding interaction which is shown more clearly in the following models.  
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 antagonist – a compound which upon binding to a receptor blocks activity identical to when the receptor is 
bound with the natural ligand 
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A pharmacophore for agonism [81] is shown in Figure 2-3.  This study details a median distance of 
6.2 angstroms between the required protonated amine and a hydrogen bond acceptor, which disagrees 
with the 7.1-8.1 angstroms proposed by the previous study [79].  This paper goes further to suggest that 
the hydrogen bond acceptor group is not crucial to agonism, as was suggested for antagonism.  It was 
also suggested that compounds showing high affinity for the receptor could overcome the lack of a 
hydrogen bond acceptor with an aromatic ring 4-4.3 angstroms from the central aromatic ring.  This 
hints at ligand interactions with either Ser 5.42 or Phe 6.51 and Phe 6.52.  These residues are all in the 
same region of the binding site, as is shown by later studies, and could accommodate either a HBA or 
HYD/AR interaction.  These findings hint at the possibility that the hydrogen bond acceptor regions 
described by these two models do not result from the same binding site interaction.  It is possible that 
after forming the salt bridge in the PA region, an HBA interaction may be possible in two different 
conformations.    These calculations provide support for multiple possible binding modes for ligands. 
Lopez-Rodriguez et al. [4] amended their initial research with a revised model (Figure 2-3) for 
antagonism which includes five regions, all deemed necessary for the antagonists to bind to the 5-HT7 
receptor.  This model improves on the previous calculation by including the aromatic groups mentioned 
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in Wilcox’s model in Figure 2-2 [80].  However, this model only describes one HBA interaction and it is 
away from the region of the binding site containing Ser 5.42, unlike that proposed by Vermeulen in 
Figure 2-3 [81].  This model did also not include the region which noted favorable steric bulk, but this 
feature is present several of the ligands used in the calculation.    [4] 
A subsequent study proposed which agrees with the evidence for two possible HBA interactions in 
the binding site suggests that there are two binding pockets of the receptor [5].  Docking studies 
confirmed the binding mode of the ligands used in the calculation.  They are conformed in a similar 
manner as previous research [4] as shown by the overlaid structure in Figure 2-4.  This recent 
pharmacophore describes in detail two different HBA interactions as described separately in previous 
research.  Shown near the right side of Figure 2-4 is the HBA interaction proposed to affect agonism of 
the 5-HT7 receptor.  Few ligands have been synthesized previously which explore this region for affinity 
and selectivity advantages.  Of these ligands include arylpiperazines, which is a common moiety in the 
library of ligands synthesized for the current study.  It was a goal of this research to synthesize ligands 
which exploit the interactions described at this secondary HBA region based on these projections.  A 
region corresponding with the hydrophobic interactions seen in the model in Figure 2-2 is also present, 
shown as a HYD/AR region on the left side of the presented model in Figure 2-4.  The central protonated 
amine region is also present. 
Many ligands exhibiting high affinity to the 5-HT7 receptor have been synthesized based on the 
predictions of these models. Table 2-1 shows a few compounds whose affinity can be described by these 
pharmacophores. The compounds listed show features of many previous 5-HT7 receptor ligand classes.  
These efforts are continued, as detailed in the next chapter, with the synthesis of a series of compounds 
which combines the most advantageous groups from each of the previously published ligand classes, as 
well as those synthesized in this lab. 
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Table 2-1. A few compounds with high affinity and selectivity to 5-HT7 are listed.  This affinity is due to optimized interactions 
between the ligands and the binding site, as described by the above pharmacophore models. 
Structure Action 
Ki (nM) 
to 5-HT7 
receptor 
pKi       
(5-HT7 
receptor) 
Selectivity 
advantages 
S
MeMe
OO
N
 
antagonist 7.9 8.1[8][6] 
>100 fold over 5-
HT1a and 5-HT2a 
receptors 
NC
NH
O
N
N
5
 
antagonist 0.63 9.2[8][7] 
>100 fold over 5-
HT1a and D2 
receptors 
N
N OH
N
O  
antagonist 32 7.5[8][8] 
>100 fold over 5-
HT1a receptor 
(Me)2N
N
N
Me
Me
Me
 
agonist 0.63 9.2[8][9] 
>100-fold over 
most, except 
some 5-HT1 
receptor family 
(Me)2N
N
N
Me
Me
Me
 
agonist 2.5 
8.6[8][10
] 
complete 
selectivity over 
140+ receptors 
 
 
2.3 Current 5-HT7 receptor ligands 
 
Using the models and projections described in the previous section, as well as other methods, 
several thousands of 5-HT7 receptor ligands have been designed and synthesized.  These compounds 
represent many different classes of 5-HT7 receptor ligands.  These ligands are the result of decades of 
research, which has been reviewed by Leopoldo [66].  This review contains a detailed account of how 
the current database of ligands came about, including the drug design strategies employed and specific 
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modifications to ligands as they developed.  These strategies are summarized, including only the most 
successful strategies and methods used to develop these ligands.  
When the 5-HT7 receptor was characterized, the only known ligand was its natural ligand, serotonin.  
This led several investigators to use serotonin as a scaffold for further modifications.  These studies 
attempted to explore the binding site of the 5-HT7 receptor by expanding the natural ligand to test the 
spatial limits of the binding site.   These studies relied on the 5-HT structure as a scaffold for 
modifications which would relay information about the nearby binding site structure.  While compounds 
designed by this method had very limited success in physiological studies, they exhibited some affinity 
to the 5-HT7 receptor.  These ligands always showed higher affinity to other receptor subtypes making 
them useless for physiological studies on the 5-HT7 receptor.    
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Table 2-2. Previously synthesized 5-HT7 receptor ligands. These compounds were important in the evolution of 
pharmacophores and the understanding of the 5-HT7 receptor binding site.  There is still room for improvement of these 
ligands, as noted in the far right. 
 
Another strategy utilized in the early stages of 5-HT7 receptor ligand development involves testing 
ligands for other receptor subtypes for affinity to the 5-HT7 receptor.  These studies showed that 
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 bioavailability – a measure of the percentage of a dosage which enters systemic circulation.  Considerations 
relating to bioavailability include metabolism and absorption into the bloodstream 
Compound 
Name 
Structure 
Ki (nM) to 
5-HT7 
receptor 
pKi  
(5-HT7 
receptor) 
Main 
receptors 
with 
selectivity 
problems 
Comments 
8-OH-DPAT 
N(Pr)
2
OH
 
500 6.3 5-HT1a 
Useful in its 
radiolabeled 
form for binding 
assays 
LY215840 
OH
N
H
N
N
i-Pr
O
Me
 
16 7.8 5-HT2a-c 
Also affected 
other 
monoamine 
receptors in 
animal studies 
SB-269970 
OH S
N
N
O O
Me
 
5.0 8.3 HT1a, HT2a 
Metabolized 
very quickly, no 
oral 
bioavailability25 
SB-656104 
S
N
O O
N
H N
Cl
 
2.0 8.7 - - 
S20244 
O
N(Pr)
2
OMe
 
16 7.8 5-HT1a 
Previously 
designed as 5-
HT1a antagonist 
SB-258719 
Me S
N
O O
Me
N
Me
Me
 
32 7.5 - - 
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compounds thought to be selective to other receptor subtypes, such as 8-OH-DPAT, also showed affinity 
to the 5-HT7 receptor [87].  This affected years of research on the 5-HT1a receptor, and immediately 
implicated the 5-HT7 receptor in many processes previously thought to be mediated specifically by the 5-
HT1a receptor [88-89].  Later studies would repeat this strategy by using existing ligands to other 
receptors as leads for new 5-HT7 receptor ligands.  In this manner, ergolines were used to explore the 5-
HT7 receptor binding site.  Optimization of these compounds led to LY-215840, as well as many others 
which showed high affinity to the 5-HT7 receptor [90].  Guillamet also used ligands to other 5-HT 
receptors as leads, such as S20244, which were modified to yield compounds showing high affinity to 
the 5-HT7 receptor [91].  These studies expanded the pool of high affinity 5-HT7 receptor ligands.  
However, the major drawback of this approach is the difficulty in achieving selectivity over the receptor 
for which the lead compound showed affinity.  Indeed all compounds derived from 5-HT1 and 5-HT2 
receptor ligands showed lower affinity to the 5-HT7 receptor than the original receptor. 
The first studies on binding site structure were used in research such as that resulting in a patent 
published by SmithKline Beecham [92]. The authors used high-throughput screening (HTS) methods to 
identify a lead for the first novel class of 5-HT7 receptor antagonists, sulfonamides.  This study optimized 
a series of sulfonamides yielding SB-258719 which exhibited modest affinity and selectivity to the 5-HT7 
receptor.  The sulfonamides were optimized further, resulting in SB-269970, which has been widely used 
for in vitro research.  Although this compound was a significant breakthrough, SB-269970 showed no 
oral bioavailability and was shown to be metabolized almost immediately in vivo.  Resulting metabolism 
research indicated this may be due to the nature of the cyclic amine (instead of the phenolic group, as 
initially thought).  This prompted modifications to the cyclic amine and resulted in the introduction of an 
arylpiperazine to the sulfonamide class of compounds.  The arylpiperazine moiety has since been seen 
throughout several ligand classes due to its affinity to the receptor.  Arylpiperazine analogs, namely SB-
656104, demonstrated slower metabolism and increased oral bioavailability. This compound showed 
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higher affinity and selectivity than its predecessors, with only selectivity to 5-HT1 and 5-HT2 receptor 
subtypes remaining problematic.  A large library of arylpiperazine 5-HT7 receptor ligands have been 
synthesized in order to optimize the selectivity over these receptors and are discussed in the following 
sections. 
After a decade of research developing new ligands and analyzing their binding profiles, the binding 
site of the 5-HT7 receptor has become more precisely defined.  Pharmacophore studies mentioned 
previously are testament to this and the general structure is thought to include aromatic/hydrophobic 
regions, hydrogen bond acceptors, a hydrophobic linker region and an interaction with a protonated 
amine.  With a significant amount of information about the 5-HT7 receptor, it is now possible to rely less 
on information gleaned from other receptors.  Research has become focused on optimizing the 
pharmacophore for antagonism and agonism, as is reflected by recent publications at this time. 
Additional computational methods are now available, including homology modeling of the receptor site 
due to available crystal structures of rhodopsin and α2 adrenergic receptors.  In this manner, 
investigators focused on analyzing each region of the pharmacophores to present novel leads through 
HTS, classes through lead optimization, and selective ligands through pharmacophore optimization.   
The optimization of several classes of compounds has yielded several novel selective antagonists and at 
least one selective agonist.  Currently, many successful ligands to the 5-HT7 receptor have been 
developed from leads representing many different classes of compounds.  These are summarized in 
Table 2-2.  Each of these compounds has drawbacks and advantages but to date there is no universal 5-
HT7 receptor ligand which possesses all advantageous properties necessary for complete physiological 
profiling.  The available binding requirements are used to design ligands with better pharmacological26 
attributes, affinity and selectivity over other subtypes.
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 pharmacological – relating to the actions of biological systems on a specific compound 
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3 SYNTHESIS 
 
3.1 Synthesis of substituted pyrimidines as a diverse set of 5-HT receptor ligands 
 
Initial studies on pyrimidine ligands demonstrated that pyrimidines exhibit high affinity to 5-HT 
receptors [93].  Pyrimidines are an optimal moiety for synthesizing a diverse set of substituted 
arylpiperazine compounds, as shown in Scheme 1.  This synthetic pathway has demonstrated to be 
effective in synthesis of substituted pyrimidines [1,2].  The commercially available pyrimidines 1a-c were 
used as starting materials in the synthesis of a novel library of 5-HT receptor ligands.  Pyrimidines 
undergo a nucleophilic attack at the partially positive 2-, 4-, and 6- positions when treated with carbon 
nucleophiles, which makes these compounds an attractive scaffold for introducing variable substituents 
to the aryl ring.  Additionally, the use of 2-chloropyrimidines 1a-c allow for the substitution to proceed 
exclusively at the 4/6-position.  This is accomplished by performing the nucleophilic addition to the 
aromatic ring at low temperatures.  These conditions ensure the reaction proceeds through addition at 
the 4/6-position as opposed to the substitution of chlorine at the 2-position of pyrimidine, due to the 
size of the 2-chloro substituent.  The substitution product was not observed as a product of any 
reaction.  A diverse library of 4- and 4,6- substituted 2-chloropyrimidines 3a-f were synthesized by 
nucleophilic addition of nucleophiles at low temperatures.  The nucleophiles were either commercially 
available or generated in situ .  This was achieved either by the abstraction of an acidic hydrogen or a 
lithium-halide exchange using a lithiated base, most commonly n-butyllithium.  During the dropwise 
addition of the appropriate chloropyrimidine dissolved in dry THF, the temperature was kept at -78: C.  
The temperature was then slowly raised until no starting material was detected by TLC.      After 
completion, the mixture was slowly quenched with a water/THF solution.  The resulting dihydro 
intermediate 2 was oxidized quantitatively with a solution of 2,3-dichloro-5,6-dicyanoquinone (DDQ).  A 
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basic workup using 1M sodium hydroxide in order to remove excess DDQ followed which allowed for 
the extraction of substituted pyrimidines 3a-f into an ethereal solution.  Compounds 3a-f were then 
isolated by preparative chromatography using a chromatotron and a mobile phase of 
hexanes/dichloromethane (typically 4:1) The substitution product was not observed as a product of any 
reaction. The substitution product was not observed as a product of any reaction..  Addition to 
substituted pyrimidines is also possible, such as shown in the synthesis of 4f.  Yields of the addition were 
in the range of 44-59% which is typically lower than previously reported for alkyl substitutions.  In the 
previous paper which details aryl substitutions to pyrimidine [2], the yields were comparable to those 
found here. 
A subsequent nucleophilic aromatic substitution of the chlorine provides facile entry to compounds 
4a-g.  This aromatic nucleophilic substitution has typically been carried out in ethanol, although the 
compounds reported showed higher yields when carried out in toluene.  In cases where toluene was 
dried using sodium metal prior to the reaction, yields were often significantly higher.  This substitution 
was effected by treating the appropriate chloropyrimidine 3a-f with an excess of N-methylpiperazine.  
The mixture was heated under reflux in toluene until the starting material was no longer detected by 
TLC.  The products were then separated into ether and purified on the chromatotron yielding 
compounds 4a-g.  The conditions of this reaction were not optimized further and resulted in yields of 
substituted arylpiperazines ranging from 32-82%.    
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Compound R1 R2 R3 
Starting 
material 
Yield 
(%) 
1a H H - - - 
1b H n-propyl - - - 
1c Cl H - - - 
3a H H t-butyl 1a 44 
3b [2] H H O
 
1a 57 
3c H H 
OEt  
1a 40 
3d [94] H H  1a 59 
3e H H 
 
1a 58 
3f H n-propyl O
 
1b (17) 
4a H H sec-butyl 1a 32 
4b H H t-butyl 1a 52 
4c H H 
O
 
1a 53 
4d H n-propyl H 1b 82 
4e H n-propyl O
 
1b 44 
4f n-butyl n-propyl O
 
3f 73 
4g N N Me
 
H 
O
 
1c 37 
 
  
30 
 
 
 
3.2 Synthesis of substituted pyrimidines by 1,4 addition to vinyl-substituted pyrimidines 
 
To further examine affinity increases seen by compounds with a hydrogen bond acceptor in a 
position analogous to that of the oxygen in 4-(3-furyl)-2-(piperazino)pyrimidine, the series of substituted 
pyrimidines was further explored.  The addition of a nucleophile to vinyl substituents, such as found in 
3d and 3e was achieved both before and after the substitution of chlorine.  In the case of compounds 
containing a vinyl moiety such as 3d and 3e, it was observed treatment with an excess of a nucleophilic 
species resulted in both substitution of the chlorine and conjugate addition to the vinyl moiety.  The 
conjugate addition of nucleophiles to pyrimidines has only been reported recently [5] despite the great 
potential for synthetic applications.  The competing substitution reaction allowed for us to observe the 
relative reactivity of the vinyl groups during conjugate addition.  When Grignard reagents were 
employed in the presence of copper(I) iodide, the substitution product was not observed.  In all other 
cases, some amount of the substitution product was observed, though typically the 1,4-conjugate 
addition was the major product.  Only in the case of nucleophiles sodium methoxide and sodium 
ethylthiolate was there no major product.  In the case of sodium methoxide addition, the substitution 
product, the conjugate addition product, and the diaddition product were observed in 19-22% yields.  
Reaction with sodium ethylthiolate only produced significant yields of the diaddition product when 
treated in excess, otherwise, low yields and many product resulted.  Treatment of the pyrimidines with 
the nucleophiles typically occurred in refluxing toluene with the exception of Grignard reagents, which 
were used at low temperatures.  Although first attempted with a catalytic amount of copper (I) iodide, 
the optimal ratio of Grignard reagent to copper iodide was determined to be 2:1.  The appropriate 
pyrimidine was then added and the mixture was stirred.  These reactions were quenched after the 
presence of starting material was no longer detected by TLC.  The products of these reactions were 
extracted into ether, concentrated, and purified on the chromatotron.  Care was taken to ensure that 
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products were analyzed for nucleophilic aromatic substitution and diaddition products. Similar 
treatment of compounds with electron donating groups did not undergo the analogous conjugate 
addition and resulted only in the substitution product.  This is exemplified by compounds 3c and 4c.  
Resulting arylpiperazine compounds are summarized by Scheme 2 and listed in the table below.  This 
synthetic pathway is especially helpful in the optimization  of 5-HT7 receptor ligands as it addresses the 
necessity of a hydrogen bond acceptor in compounds such as 6i.  Modifications of this group have 
supported current hypotheses about the nature of this interaction.  Further study may reveal additional 
information unique to the 5-HT7 receptor resulting in a ligand with increased selectivity..  
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N
NCl
R
N
NCl
R
Nu
N
N
R
NuN
N
Me
Nu- or NuH N-methylpiperazine
toluene
Scheme 2.
3d, 3e 5a (25%):  R = Ph, Nu = OMe
5b (61%):  R = Ph, Nu = Ph
6a-n
 
 
Synthesized under the direction of Dr. Lucjan Strekowski by Elizabeth Raux
a
 or Ava Blake.
b
 
 
3.3 Synthesis and facile modification of  2-chloro-4-(acetyl)pyrimidine  
 
Although compound 3c did not undergo conjugate addition, as with other pyrimidines with a vinyl 
moiety, further modifications to this substituent were available.  The resulting analogs are summarized 
in Scheme 3.  As shown, 3c can be hydrolyzed to 4-acetylpyrimidines in high yields, such as 7.  This was 
Compound Nucleophile R Yield (%) 
6a NH N Me
 
H 22 
6b 
NH
2
 
Ph 57 
6c EtS-Na+ Ph 37 
6da Me2NH H 55 
6eb n-BuNH2 H  
6fb t-BuNH2 H  
6ga 
NH
2
 
H 62 
6hb NH N
 
H  
6ia MeO-Na+ H 55 
6ja EtS-Na+ H 25 
6kb 
S-Na+
 
H  
6l MeMgBr Ph 39 
6ma MeMgBr H 56 
6na PhMgBr H 77 
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achieved by treatment of either 3c or the substitution product 2-(N-methylpiperazino)-4-(1-
ethoxyvinyl)pyrimidine with 10% methanolic HCl.  The acidic mixture was stirred at room temperature 
until the presence of starting material was no longer detected.  The hydrolysis of 3c was performed prior 
to the substitution with N-methylpiperazine in order to avoid forming salts of the products during the 
reaction.  For all products 5 and 6a-c, compound 3c was hydrolyzed before the nucleophilic aromatic 
substitution of chlorine as before.  This gave the acetyl compound 8 which is highly functionalizable and 
gives access to a diverse set of ligands such as compounds 9a-c in yields comparable to those previously 
reported.  As with compounds 6a-6c, this synthesis allows for a heteroatom to be inserted into the 
analogous position of previous high affinity 5-HT7 ligands.  Examining the affinity of these compounds 
will give further information on the nature of binding site interactions with currently available ligands.  
This information will lead to further optimizations. 
Compounds 9a-c were synthesized by treatment of 8 with the appropriate hydroxylamine or hydrazine 
compounds.  This reaction was carried out in refluxing methanol with potassium carbonate.  After no 
starting material remained, the products were extracted into ether and purified on a chromatotron.  The 
aim was to synthesize both E and Z stereoisomers of compounds 9a-c by varying the size of the base 
used in the reaction, but this was not the case [95].  Compound 9a was synthesized using both sodium 
hydroxide and sodium acetate as the base.  The 1H NMR spectra for both products were identical, 
indicating that only one isomer was synthesized.  In order to determine which isomer was synthesized, 
the structure of compound 9a was analyzed by NOESY.  No crosspeaks between the hydroxyl group and 
the aromatic proton or methylene protons of the piperazine were observed.  Crosspeaks in the spectra 
are seen between the protons of adjacent methylene protons of the piperazine.  While the absence of 
expected crosspeaks correlating to the Z-isomer structure may be due to proton exchange with the 
solvent, compounds 9a-9c are assumed to exist exclusively as E-isomers.  This is in accordance with their 
lowest energy conformation.   
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N
NCl
OEt
N
NCl Ac
N
NN Ac
N
Me
N
NN
N
Me
N
Me X
R
H+ N-methylpiperazine
toluene
Scheme 3.
N-X-R
K2CO3
3c 7 8 9a-c
59% 70%
 
Compound X R Yield (%) 
9a O H 76 
9b N H 76 
9c O Et 29 
 
 
3.4 Synthesis of 5-HT7 receptor ligands with piperazine extensions 
 
In addition to synthesizing analogs with substitutions at positions around pyrimidine, it is prudent to 
further explore the binding site of the 5-HT receptors by extending the piperazine substituents.  
Previous studies have shown that extending these ligands result in active compounds.  Indeed, some of 
the most active and selective compounds belong to the class of long chain aminopiperazines, as 
classified by Kolaczkowski [77].  It is also hypothesized that by increasing the size of the ligands, the 
interactions with the binding site can be maximized.  This should have the effect of increasing selectivity 
as well as affinity.  These compounds were synthesized by treating the highly active 2-chloropyrimidine 
3b with several commercially available N-substituted piperazines.  This substitution yielded compounds 
10a-m in 16-87% yields. 
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N
NCl
O
N
NH
R N
NN
ON
R
toluene
3b 10a-m
Equation 1.
 
 
Synthesized under the direction of Dr. Lucjan Strekowski by Sam Barnes
a
 
 
 
 
Compound R Yield (%) 
10a H 56 
10b Et 61 
10c propyl 39 
10d benzyl 73 
10e 
MeO
 
87 
10f 
MeO  
40 
10g 
Cl
 
36 
10h 
Cl  
60 
10i 
O  
33 
10j 
t-Bu
 
45 
10k 
 
22 
10l 
N
N N
O N
 
16 
10ma phenyl  
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3.5 Synthesis of fused ring 5-HT7 receptor ligands 
 
Benzofuran derivatives of arylpiperazino compounds were synthesized in order to increase the 
rigidity of the structure compared to furyl-substituted pyrimidines which showed high affinity.  
Specifically, by eliminating the possibility for rotation between the heteroaryl rings, more detailed 
information could be obtained about the binding interaction resulting in high affinity to 5-HT7 and 5-HT2a 
receptors.  As before, this information gives insights into designing future ligands with increased affinity 
and selectivity to the 5-HT7 receptor.  These benzofurans were synthesized according to Scheme 5.  The 
appropriate bromophenol was treated with an aqueous solution of potassium hydroxide in DMSO to 
form the bromophenoxide.  This basic solution was then treated with 2-bromo-1,1-diethoxyethane and 
heated under reflux until no starting material remained.  Extraction into ether and subsequent washings 
with 5% aqueous sodium hydroxide gave the substitution products 12a-e, in quantitative yields.  In most 
cases the products were used without purification.  This was followed by a ring closure reaction under 
acidic conditions.  Compounds 12a-e dissolved in a solution of chlorobenzene and polyphosphonic acid.  
This solution was refluxed for 12h resulting in a thick black solution.  The acid enables the benzene ring 
to exist with a positive charge as an aromatic bond attacks the partially positive carbon of the diethoxy 
group.  Two intramolecular eliminations of ethanol oxidize the intermediate to the benzofurans 13a-e.  
The products were decanted from a large amount of remaining tar, which was washed several times 
with diethyl ether.  This organic solution was then neutralized by washing with a 1M aqueous sodium 
hydroxide solution.  Purification on a chromatotron yielded the bromobenzofurans 13a-e in 23-31% 
yields, which are comparable to those previously reported for the synthesis of benzofurans[8][11].   
These halogenated benzofurans were then subjected to a Buchwald-Hartwig coupling [97] with N-
methylpiperazine to give the arylpiperazino analogs 14a-e.  The Buchwlad-Hartwig coupling reaction 
exploits a palladium catalyst which inserts into an aryl halide bond, such as those found in 13a-e, leaving 
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the aromatic group susceptible to substitution by N-methylpiperazine.  This reaction was carried out in 
dry toluene by treating compounds 13a-e with N-methylpiperazine in the presence of tert-butoxide, the 
catalyst tris(dibenzylideneacetone) dipalladium(0) and the ligand racemic 2,2’-bis(diphenylphosphino)-
1,1’-binaphthyl.  These reagent participated in the catalytic cycle illustrated below.  To summarize, the 
palladium catalyst undergoes oxidative addition to insert into the aryl halide bond.  This results in 
oxidation of the palladium(0) complex to palladium(II).  A t-butoxide ion then replaces the more stable 
halide.  A reversible proton exchange between the t-butoxide group and N-methylpiperazine results in 
the secondary amine and the aromatic group bound in complex with palladium.  As the amine and the 
electron deficient aromatic group are coupled, the palladium(II) complex undergoes reductive 
elimination to give the final product.  Altering the conditions of the reaction with consideration to the 
base and the ligands used often results in increased yields.  This was not the focus of this study, 
however, and the yields were found to be acceptable.  Due to this, the yields are coparatively low with 
other similar syntheses, but would likely increase were the reaction conditions optimized.  After 
refluxing until the starting material was no longer detected, water was added and the products were 
separated into diethyl ether.  Purification of the products on a chromatotron yielded arylpiperazines 14 
in 34-46% yield.  The yields of these coupling reactions can be improved through optimization of the 
ligand and base used.  However, optimization of this coupling reaction was outside the scope of this 
project. 
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Figure 3-1.  The catalytic palladium cycle. 
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Scheme 4.
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Compound R1 Starting Material Yield (%) 
14a N
N
Me
O
 
11a 38 
14b N
N
Me
O
 
11b 38 
14c N
N
Me
O
 
11c 34 
14d [12] 
O
N
N
Me  
11d 39 
14e 
O
N
N
Me
Me
 
11e 46 
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3.6 Synthesis of bivalent 5-HT7 receptor ligands 
 
Many previously synthesized N-substituted arylpiperazines have shown high affinity to 5-HT 
receptors.  In fact, several classes of compounds exist which exploit the arylpiperazine moiety in 
selective 5-HT7 receptor ligands.  This research has focused on the optimization of the arylpiperazine 
interaction with the 5-HT7 receptor to increase affinity and selectivity.  It is logical to combine the most 
successful arylpiperazine moieties with previously noted classes of compounds such as sulfonamides, 
oxindoles and hexanamides.  This strategy has resulted in the design of a novel set of ligands which 
contains moieties optimized for each proposed binding site interaction.  Ongoing research on the 
activity of these compounds will clarify which structural characteristics are required for selective 
agonism and antagonism of the 5-HT7 receptor.  Study of these ligands may also yield information about 
the receptor mechanism for agonism and antagonism by comparing the activities of agonists such as AS-
19 with their extended analogs.  Synthesizing a series of extended ligands based on known agonists will 
test this theory. 
New analogs to existing classes of compounds have been synthesized and shown to bind to the 5-
HT7 receptor.  These classes contain previous examples of arylpiperazine moieties.  Replacing these 
arylpiperazines with the optimized ligands synthesized as above, such as 10a, is expected to produce 
ligands with much higher affinity to the 5-HT7 receptor while decreasing affinity to other similar 
receptors.  These compounds (17a-b) are shown in Scheme 6 below and were prepared from the 
previously described precursors.  For each of these compounds, the synthetic strategy was to prepare 
the corresponding halide to compounds representative of each ligand class.  These halides are shown in 
Scheme 5 and were synthesized according to the literature.  The relative length of the alkyl linker differs 
in all cases, and gives a more accurate description of the overall binding site size.  All compounds have 
groups which represent the proposed interactions for this region of the binding site, such as the 
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aromatic/hydrophobic region of the benzene groups and an adjacent hydrogen bond acceptor as was 
described in the pharmacophore review.  
S
i-Pr
S
i-Pr
O O
S
Me
O O
Me
Br
BrBr
NH
2
NC
Cl
Br
O
N
Br
O
NC
m-CPBA 1. n-BuLi
2. 
15
Scheme 5.
+
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60%  
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Me N
NH
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O
t-Bu
N
N
O
O
O
t-Bu
Me
NH
N
O
Me
R Br
N
N
O
Me
R
TFA
13e 14f
14g
Scheme 6.
(15 or 16)
17a (30%):  R-Br = 15
17b (28%):  R-Br = 1651% 88%  
The synthesis of these precursors to the eventual 5-HT7 receptor ligands has been reported 
previously.  These procedures were repeated, modifying when necessary.  The synthesis of the sulfone 
followed Scheme 6.  The sulfone was synthesized beginning with the oxidation of isopropyl phenyl 
sulfide.  This was achieved by treating a solution of isopropyl phenyl sulfide in dichloromethane with m-
chloroperoxybenzoic acid.  This reaction typically proceeds at room temperature, but in this case mild 
heating was used in order to ensure the efficient reaction of the oxidizing agent.  After the reagents 
were consumed, the reaction was quenched with sodium sulfite and the products were separated and 
washed with subquent portions of aqueous basic, acidic, and brine solutions.  The products were then 
distilled to give the sulfone in good yield.  This oxidized species was then treated with n-butyllithium in 
the next step to yield the carbon nucleophile.  Once generated, this nucleophile was treated with 1,4-
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dibromopropane at low temperatures, similar to the previous additions of carbon nucleophiles, to give 
the substitution product. 
The remaining precursors were prepared by nucleophilic substitution of a halide with a 
commercially available amine.  In the case of the hexanamide, a basic solution of the amine was stirred 
during the addition of acyl chloride.  This readily gave the product as a white precipitant in the reaction 
mixture, as the pH of the solution was maintained by continuous addition of an aqueous sodium 
hydroxide solution.  The products were separated into dichloromethane and purified by recrystallization 
to give the hexanamide precursor in good yield.  The oxindole followed a similar procedure by treating 
the a solution of commercially available oxindole in acetonitrile with 1,4-dibromobutane.  This was done 
in the presence of potassium carbonate to enhance the nucleophilicity of the amide.  The mixture was 
heated until the presence of starting material was no longer detected by TLC.  Purification on a 
chromatotron yielded the substitution product in adequate yield.  It was found that when concentrated, 
this product decomposed into an intensely magenta colored compound.  This decomposition occurred 
over the span of minutes and therefore, the product was stored as a solution in acetonitrile.  This 
method sufficiently prevented decomposition. 
These bromides were then treated with the appropriate amines, whose preparation has been 
detailed elsewhere.  This was achieved by refluxing the reagents in the presence of base until the only 
product was detected by TLC.  The dimeric substitution products 17a-b, were then separated into ether 
and purified on a chromatotron.  
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4 MODELING 
 
4.1 Calculation of models for 5-HT7 and 5-HT2a receptors 
 
Three-dimensional quantitative structure-affinity relationship (3D-QSAR) analysis is a powerful 
strategy to elucidate interactions between ligands and the binding site [99].  The objective of this 
analysis is to calculate a statistically significant correlation between the structural properties of a large 
set of ligands and the binding affinity to serotonin receptors.  In order to determine a meaningful 
correlation, the structure of each ligand must be represented accurately and quantitatively.  The 
structure can then be analyzed mathematically and the results can be represented in a straightforward 
manner allowing for prediction of ligands with higher affinity and more detailed descriptions of the 
receptor binding site.  While 3D-QSAR methods are a powerful tool for analyzing binding site structure 
and interactions, there are drawbacks which arise from necessary assumptions.  Among these is the 
assumption that there is only one binding mode for a group of ligands due to the dependence of 3D-
QSAR on the alignment of all compounds in an analogous manner.  If two compounds do not bind in the 
same way, then comparing their affinity based on a common set of binding site interactions is not valid.   
In the same manner, it is assumed that each compound binds the receptor in its lowest energy 
conformation.  Ligands which bind in other conformations observe a decrease in apparent binding 
affinity corresponding to the resulting energy change.  This may significantly affect the affinity and result 
in skewed results.  Also, it is common to assume that the ligands bind to the receptor in their lowest 
energy conformation.  Any perturbations from this conformation upon binding are reflected as an 
increase in the experimental Ki and result in the generation of artificial regions in the model.  This is a 
concern in this study, and is discussed further. 
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4.1.1 Validation of QSAR methods 
These 3D-QSAR methods assign values to ligand structures by evaluating potential energy functions 
at many points in a regularly spaced grid.  A probe atom [100] is placed at each lattice point of the grid 
and the overall potential energy of the probe and the ligand is calculated.  The systematic evaluation of 
the energy function at all points in the grid results in a numerical representation of the three-
dimensional steric and electrostatic features of each ligand.  These values can then be correlated with 
the experimental data to determine which combinations of structural properties are most effective.  3D-
QSAR has been most effective when undertaken by either comparative molecular field analysis (CoMFA) 
or comparative molecular similarity index analysis (CoMSIA) methodologies [101].  Both CoMFA and 
CoMSIA methods operate on the same basic principles, however they differ in the way structural data is 
assigned and evaluated [102].  CoMSIA methods rely on functions which eliminate the possibility of 
unreasonably large calculated energy potentials at grid points.  This poses a significant challenge in 
CoMFA studies [103].  The end result of these field calculations is a much smoother function, which 
leads to contour maps that are more contiguous and easier to interpret [104].  Many studies have 
analyzed data by both methods [105-107].  In the vast majority of these studies, the predictivity of 
calculated CoMSIA models was comparable or exceeded that of CoMFA models.  CoMSIA models are 
also more resistant to small changes in the absolute positions of the ligands by systematic shifts and 
rotations of the aligned database of ligands [108].  CoMSIA methods also have the advantage of using 
several functions which are typically not included in CoMFA studies, such as hydrophobicity, and 
hydrogen bond donor and acceptor fields [109].  The separation of these characterisitics from steric and 
electrostatic fields calculated in CoMFA studies provides more detailed information about the ligand 
structure and subsequently the receptor binding site.  For these reasons, CoMSIA methods were used to 
evaluate the data. 
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4.1.2 Statistical parameters 
 In essence, calculating a 3D-QSAR model is a problem of multivariate regression analysis.  This is 
to say that a dependent variable (the pKi of the ligand) is to be calculated from a set of many 
independent variables (the set of coefficients used to describe the ligand structure) [110].  This 
correlation is typically calculated by means of a partial least squares (PLS) analysis and can be 
represented by the formula y = f(x), where the calculated QSAR model is the function [111].  PLS is 
popular for this type of calculation due to its ability to handle a large amount of dependent variables.  
Using only the most significant of the dependant variables allows most of the noise to be removed from 
the model.  This is achieved by a complex series of functions which compiles the most relevant structural 
data into a minimum number of dependent variables, or principal components27 (N) [112]. A model that 
uses fewer principal components to accurately describe a function is more predictive, based on the 
input information.  However, if too few components are used, the model may not reflect vital 
information to describe all the regions present.  The optimum number of components is determined by 
a calculating the r2 of the experimental vs. predicited activity across a range of principal components.  
The leave-one-out (LOO) procedure was chosen for internal validation of the data set and has been 
shown to be effective [113].  This analysis calculates the predicted residual sum of squares (PRESS) along 
with cross-validated r2 (q2) using a range of components.  The number of components which 
corresponds to the lowest PRESS is typically used in calculations.  However, if reasonably similar PRESS 
values are returned from a smaller number of components, this number may be used in order to reduce 
noise in the model.  The predictivity of the PLS analysis can be evaluated by several statistical factors, 
most importantly q2, the correlation constant (r2), and F-value [114].  Values of q2 higher than 0.5 are 
considered to be acceptable for a significant model, although this parameter along does not adequately 
                                                          
27
 principal component – an algebraic matrix which represents compiled information about ligand structure for 
QSAR analysis 
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describe the predictivity of the model [115].  The F-test provides further support of a model, with higher 
values signaling a more predictive model.  This statistical test gives the explained variance relative to the 
unexplained variance in the calculated model.  The correlation coefficient shows the linearity of the data 
and is typically between 0.7 and 0.9 for predictive models.  In addition to these parameters, a qualitative 
analysis of the graph of predicted vs. observed activity is common.  Also, discussions of residuals and 
outliers help to support the evidence for a predictive model.  The strength of this analysis directly 
corresponds to the confidence with which future ligands’ activity can be predicted. These conventions 
are followed in this research and have showed these models to be statistically valid for predicting 
ligands with higher affinity and selectivity to the receptor being studied. 
4.1.3 Ligands used to calculate the models   
The structures used to calculate the 3D-QSAR models are listed in Tables 4-1 through 4-6 below.  
These tables have been organized based on their structural features.  Ligands and their experimental 
data were obtained from the 5-HT7 receptor ligands previously synthesized at Georgia State University.  
Compounds which were not included in the synthesis of this project are labeled as they were named by 
their author.  The binding assay calculated the affinity as either Ki or Ks, the former of the two being 
more precise, with a reported standard error of measurement of 20% [116].  The error associated with 
Ks values is quite large and therefore, only compounds with experimental Ki values were used in the 
QSAR study.  Ligands whose pKi was less than 5 were not included.   To calculate a robust QSAR model, it 
is necessary to consider ligands exhibiting a large range of affinity to the receptor.  The database of 
compounds shows affinity ranging over five orders of magnitude.  This range has yielded predictive 
models in several other studies [117-120].  This exclusion left 67 of the 104 ligands synthesized at 
Georgia State University available for analysis.  These compounds are shown in Tables 4-1 through 4-6 
below. 
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Several ligands were omitted from the QSAR study for structural reasons, such as chirality. Chiral 
structures have been problematic in CoMSIA calculations [121] as enantiomers often can exhibit 
significantly different affinity to 5-HT receptors [122].  The only compound with a chiral center in the 
synthesized ligands (JS47) was omitted from the library.  Compounds which could not be minimized to 
the alignment which was used for the analysis were also omitted.  This is not meant to imply that these 
compounds cannot conform to fit the binding site for these receptors.  Including misaligned compounds 
in a QSAR analysis can provide misleading regions of interactions in the calculated model.  These 
compounds are 4f, SB14, SS05 and 10i.  Compound JK11 contains a bulky alkyl substituent at the 5-
position of pyrimidine which prevents the 6-position alkyl group from being minimized into an alignment 
similar to other alkyl groups at this region.  Compound SB14 was omitted due to its aromatic 
substituent.  This structure contains adjacent aromatic groups in the 4-position of pyrimidine which 
cannot minimize into a planar arrangement, as in high affinity compounds such as AR02.  Compounds 
which do not contain basic nitrogens were also excluded as this group has been previously shown to be 
crucial for binding and can be observed qualitatively by examining the large decrease in affinity of 
compound 10i and 10m compared to similar compounds.  Compound SS05 was also excluded due to the 
poor alignment of the crucial tertiary nitrogen which acts as the protonated amine at the receptor to 
form a salt bridge.  This interaction is well known and used as a point of reference in the analysis of the 
calculated models.  The remaining 63 compounds were used in the study where experimental affinity 
data was available.  Omitted compounds are highlighted in gray.   
All subsets of pyrimidine analogs were drawn using SYBYL’s (Tripos, Inc) sketch editor and stored in a 
molecular spreadsheet. To calculate a meaningful correlation by CoMSIA methods, structures must be 
realistically represented with regard to several steric and electrostatic factors [123,124].  Representation 
of individual atoms and bonds by atom typing is one method of describing the local physiochemical 
features of a molecular structure.  The atom types as defined by SYBYL represent atoms in different 
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environments such as carbons with differing hybridizations.  In all cases, atom types assigned by SYBYL 
were deemed to adequately represent ligand structure.  Protonation of the structures was also 
considered in drawing the structures as the active species of the compounds likely contains a 
protonated amine [77,79,81].  However, protonation often causes problems in QSAR methodologies 
arising from inaccuracies in calculating the molecular fields [125].  To determine whether ligands should 
be represented in their protonated or unprotonated forms, CoMSIA models were calculated from both 
protonated and neutral structures.  The pKa of the ligands was estimated based on previous studies 
[126], and in all cases, a positive charge on the tertiary nitrogen not adjacent to the pyrimdine ring was 
appropriate.  Ligands containing amides or nitrogens adjacent to phenyl rings were not protonated due 
to the low basicity of these compounds at physiological pH [127].  Comparisons between the 
contribution of the calculated fields and the predictive r2 of both models show that the neutral 
representation of ligands provides a reasonable model.  Therefore, the structures were represented in 
their unprotonated form for the model calculations.   
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Table 4-1. Shown are 4- and 4,6- substituted 2-N-methylpiperazinopyrimidines used to calculate the 3D-QSAR model for 
affinity to the 5-HT7 receptor.  Compounds omitted from the analysis based on structural features are highlighted gray. 
N
N
Me
N
N
R2
R1
 
R1 R2 
Ki (nM) 
5-HT2a 
Ki (nM) 
5-HT7 
pKi  
(5-HT2a) 
pKi  
(5-HT7) 
AR02 H O
 
20 7 7.70 8.14 
SS06 H 
O
 
562 1023 6.25 5.99 
LS104 H 
S
 
209 631 6.68 6.20 
NB45 H S
 
191 209 6.72 6.68 
AR43 H 
S
S
 
- 1000 - 6.00 
AR03 methyl O
 
22 50 7.66 7.30 
AR09 CF3 O
 
8 8 8.11 8.08 
AR30 ethyl O
 
12 7 7.92 8.15 
AR13 n-butyl O
 
2 2 8.72 8.80 
JS41 n-hexyl O
 
0 3 9.52 8.48 
JS47 sec-butyl O
 
4 27 8.44 7.57 
AR04 O
 
O
 
- 22 - 7.66 
JS49 
 
O
 
0.1 - 10.00 - 
EAR-II-62 ethyl 
O
 
251 380 6.60 6.42 
4g N N Me
 
O
 
871 1148 6.06 5.94 
EAR-II-69(2) n-butyl S
 
7 15 8.15 7.82 
GD01 n-hexyl 
O Me
 
135 83 6.87 7.08 
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Table 4-1, continued. 
JS17 n-hexyl 
O
Me  
41 12 7.39 7.92 
JS06 H O
Me
 
389 1905 6.41 5.72 
JS10 H 
O
Me  
617 457 6.21 6.34 
JS02 H 
O Me
 
1905 4266 5.72 5.37 
AR01 Cl 
O
 
- 129 - 6.89 
AR05 Cl S
 
- 295 - 6.53 
SB12 H 
S
S
 
14125 1950 4.85 5.71 
SB14 H 
 
575 4074 6.24 5.39 
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Table 4-2. Shown are compounds containing substituents which extend from piperazine used to calculate the 3D-QSAR 
model for affinity to the 5-HT7 receptor.  Compounds omitted from the analysis based on structural features are highlighted 
gray. 
N
NN
N
R1
O
 
R 
Ki (nM) 
5-HT2a 
Ki (nM) 
5-HT7 
pKi  
(5-HT2a) 
pKi  
(5-HT7) 
10a H 14 9 7.85 8.05 
10b ethyl 19 10 7.72 8.00 
10c propyl 17 5 7.77 8.28 
10d benzyl 33 7 7.48 8.18 
10e 
MeO
 
776 74 6.11 7.13 
10f 
MeO  
151 50 6.82 7.30 
10g 
Cl
 
2089 98 5.68 7.01 
10h 
Cl  
2630 83 5.58 7.08 
10i 
O  
6026 1479 5.22 5.83 
10j 
t-Bu
 
5754 7079 5.24 5.15 
10k 
 
288 49 6.54 7.31 
E178 
Me
N
N O
 
2951 209 5.53 6.68 
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Table 4-3.  Shown are the compounds containing substituents other than N-methylpiperazine at the 2-position of the 
analogous central aromatic ring used to calculate the 3D-QSAR model for affinity to the 5-HT7 receptor.  Compounds omitted 
from the analysis are highlighted in gray. 
Compound Structure 
Ki (nM)  
5-HT2a 
Ki (nM)  
5-HT7 
pKi 
(5-HT2a) 
pKi 
(5-HT7) 
JS07 
N
NN
O
NMe
Me  
- 9333 - 5.03 
JS11 
N
NN
O
Me
NMe
 
1122 2754 5.95 5.56 
AR39 
N
N
O
N
N
Me  
316 148 6.50 6.83 
GD02 
N
NN
N
Me
O
Me
 
- 263 - 6.58 
JS18 
N
NN
N
Me
O
Me
 
- 195 - 6.71 
SS05 
N
NN
H
O
N
 
7413 8128 5.13 5.09 
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Table 4-4. Shown are the benzenes and pyridines used to calculate the 3D-QSAR model for affinity to the 5-HT7 receptor.  
Compounds omitted from the analysis based on structural features are highlighted gray.  
N
N R2
R1
N
Me  
R1 R2 
Ki (nM) 
5-HT2a 
Ki (nM) 
5-HT7 
pKi 
(5-HT2a) 
pKi 
(5-HT7) 
AB-B51 H O
 
41 17 7.39 7.77 
AB-B48 H S
 
89 79 7.05 7.10 
AB-B67 H 
S
 
151 398 6.82 6.40 
E1572 methyl O
 
62 8 7.21 8.10 
EAR-II-158(3) methyl 
S
 
115 117 6.94 6.93 
AB-B72 H 
O
 
331 309 6.48 6.51 
EAR-II-166(8) methyl 
O
 
447 138 6.35 6.86 
NN R2
R1
N
 
R1 R2 
Ki (nM) 
5-HT2a 
Ki (nM) 
5-HT7 
pKi 
(5-HT2a) 
pKi 
(5-HT7) 
AB-B68 H O
 
162 11 6.79 7.96 
AB-B47 H S
 
676 74 6.17 7.13 
AB-B73 H 
O
 
1950 1122 5.71 5.95 
N R2
R1
N
 
R1 R2 
Ki (nM) 
5-HT2a 
Ki (nM) 
5-HT7 
pKi 
(5-HT2a) 
pKi 
(5-HT7) 
EAR-II-136(2) n-butyl 
S
 
195 741 6.71 6.13 
E1712 O
 
O
 
33 339 7.48 6.47 
EAR-II-173 methyl phenyl 209 2884 6.68 5.54 
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Table 4-4, continued. 
EAR-II-175(6) methyl 
S Me
 
851 2188 6.07 5.66 
EAR-II-134 n-butyl 
O
 
107 741 6.97 6.13 
E129 n-butyl O
 
68 107 7.17 6.97 
E1032 methyl 
S
 
331 295 6.48 6.53 
E1052 H 
O
 
646 912 6.19 6.04 
E1262 n-butyl S
 
46 263 7.34 6.58 
E1352 methyl 
O
 
912 309 6.04 6.51 
 
 
 
Table 4-5. Shown are benzofurans used to calculate the 3D-QSAR model for affinity to the 5-HT7 receptor.  Compounds 
omitted from the analysis based on structural features are highlighted gray. 
Compound Structure 
Ki (nM) 
5-HT2a 
Ki (nM) 
5-HT7 
pKi  
(5-HT2a) 
pKi  
(5-HT7) 
14a N
N
Me
O
 
- 3631 - 5.44 
14b N
N
Me
O
 
35 2291 7.46 5.64 
14c N
N
Me
O
 
83 4677 7.08 5.33 
14d N
N
Me
O
 
145 204 6.84 6.69 
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Table 4-6. Shown are the compounds with substituents to the central aromatic ring in the para-position to N-
methylpiperazine used to calculate the 3D-QSAR model for affinity to the 5-HT7 receptor.  Compounds omitted from the 
analysis based on structural features. 
Compound Structure 
Ki (nM) 
5-HT2a 
Ki (nM) 
5-HT7 
pKi  
(5-HT2a) 
pKi  
(5-HT7) 
4f N
NN
N
Me
O
 
240 1288 6.62 5.89 
E1405 
N
N
Me
S
 
68 224 7.17 6.65 
E149 
N
N
Me
O
 
1318 17378 5.88 4.76 
 
4.1.4 Binding mode conformation 
In order to make valid comparisons between ligand structures and the binding site, the 
conformation of the ligands represented in the model must mimic that of the receptor-bound 
conformation.  The ligands synthesized for this study have been designed to limit the amount of 
conformational ambiguity present by including structurally rigid groups, such as pyrimidine.  In most 
ligands, there are three regions where differing conformations must be considered.  These correspond 
to the 2-, 4-, and 6-, positions of the central pyrimidine or analogous central ring.  The rotation of each 
substituent with respect to the central ring is crucial to the resulting alignment.  Similar substituents 
must be minimized to a similar conformation so that during alignment, optimal overlap of features is 
observed.  Considerations with respect to the conformation of ligands are outlined below and thought 
to be reasonable based on previous research, cited where appropriate. 
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Each of the arylpiperazines have been minimized so that their basic nitrogens overlap in the same 
region.  Any structures containing a similar group, such as homopiperazine, were minimized in a 
conformation which maximized the overlap of the basic nitrogens. Structures with extended piperazine 
groups (10a-m) were minimized to extend from the chair position of the ring in the equatorial position.  
A small displacement between analogous alkyl (10c) and benzyl (10d) piperazino substituents was 
observed, though these compounds likely bind in the same manner.  This displacement was minimal and 
caused no disruption in the calculated model with respect to this region.  In the same manner alkyl 
substituents were minimized in a planar arrangement with the central aromatic ring, and extended 
toward the piperazino substituent.   
In order to distinguish between the symmetrical positions of substituents to pyrimidines and 
analogous aromatic groups, one side of the ring was designated to contain the best hydrogen bond 
acceptor.  Alkyl and steric substituents were aligned to the opposite side of the central aromatic ring.  
The intention is to separate as best as possible hydrogen bond acceptors from hydrophobic groups to 
gain separate information about interactions with residues Ser 5.42 and Phe 6.51 and Phe 6.52.  This 
was difficult in some cases, such as with AR02, where the furyl ring may be beneficial to both 
interactions.  All aromatic substituents to the central ring were minimized in the hydrogen-bond 
acceptor position, giving furyl substituents priority in this region. 
Conformation of aromatic substituents was complicated by differing lowest energy conformations of 
2-furyl and 3-furyl substituents.  Also, a large difference in Ki is observed between the two isomers.  
Compounds containing a 3-furyl substituent showed as much as a 100-fold increase in affinity to the 5-
HT7 receptor compared to their 2-furyl analogs.  Conformational studies on these compounds have been 
performed previously [128] and have shown that these analogs exist in two different conformations, 
designated s-cis and s-trans, as shown in Figure 4-1 [129].  The energy profiles of these two isomers 
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were calculated in SPARTAN (Wavefunction, Inc).  The 2-furyl analogs are shown to prefer the s-trans 
conformation, while 3-furyl analogs are at a global minimum in the s-cis conformation, albeit by a 
relatively small margin.  The implications of this different lowest energy conformation on the 
interactions with the binding site and the experimental Ki is discussed later.  For the QSAR study, it is 
prudent to minimize all analogs to the same comformation.  Therefore, all furyl and thienyl analogs to 
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the s-cis conformation of the more active 3-furyl analogs resulted in a statistically significant model.  
Care must be taken in the interpretation of the generated contour maps, specifically with regard to the 
position of the electrostatic interactions between the receptor and the furyl heteroatom.  
In all other instances of arbitrary and minimal disagreement between conformations, efforts were 
made to minimize the structure to an analogous conformation as that adopted by the highest affinity 
ligands such as AR13.  Most compounds were easily adapted to the described conformations, however 
some compounds were more problematic and required additional attention.  These compounds were 
handled on an individual basis by searching through many local minima to find one that corresponded 
well to the common alignment of structures.  These compounds include those with flexible substituents 
in the place of piperazine (SS05) as well as structures with bulky aromatic substitutents to the central 
aromatic ring.  
The overall conformational assignment of the structures is considered to be reasonable.  The 
conformation of AR13 shown in Figure 4-2 is representative of the general conformation and compares 
well with previous binding site descriptions.   Subsequent CoMSIA models and pharmacophores also 
support the conformation as a good fit for the proposed binding site structure. 
 
Figure 4-2 AR13 is shown in the conformation used for the calculation of the QSAR models.  The alkyl chain extends planar 
with the central ring, the furyl group is in the s-trans conformation, and the piperazine adopts the chair conformation with N-
substituents in the equatorial position.  
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4.1.5 Alignment of structures 
Alignment of the structures in a CoMSIA study is the most vital aspect of calculating a predictive 
model.  Without an accurate alignment, structural features cannot be meaningfully correlated.  Several 
methods have been developed in order to achieve this alignment.  In the current study, the minimized 
structure of AR02 was used as a template for alignment.  A root-means squared (RMS) fit of a common 
set of atoms from this template was used to individually align the structures to the same position.  This 
method has been shown to produce predictive models, especially from models which lack of diversity.  
The set of structures allowed for reasonable alignments without considering multiple possible binding 
modes.  This final alignment was further supported by a statistically significant model.  All structures 
used to calculate the model are shown as aligned to the template in Figure 4-3. 
 
Figure 4-3. All structures used to calculate the CoMSIA model aligned to a common template of atoms. 
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4.2 Presentation of QSAR models  
 
4.2.1 Pharmacophores 
There have been several pharmacophore models calculated for affinity [78,80] and selectivity [77,130] 
of 5HT7 receptor agonists [81,131] and antagonists [4,79].  The 5-HT7 receptor pharmacophore has 
evolved from a single region, a central protonated amine (PA), into a detailed map containing multiple 
regions.  These models for binding the 5-HT7 receptor have considered a diverse set of ligands and 
include interactions across the binding site.  These models have led to a better understanding of the 
binding mode for several different classes of 5-HT7 receptor ligands, including arylpiperazines.  The 
GALAHAD module in SYBYL was employed to analyze several of the most active ligands in the database, 
shown in Table 4-7.  Each structure in the table had been previously aligned to maximize the overlap of 
similar regions.  The standard parameters suggested by SYBYL were not adjusted as each was reasonable 
for this research.  Models to each receptor were calculated and found to be statistically identical.  These 
models were calculated from similar structures, so it was not unexpected that the calculations did not 
return significantly different models.  Therefore, the model for affinity to the 5-HT7 receptor is used to 
discuss the binding site interactions exploited by the synthesized ligands.  The calculated model (A) is 
shown in Figure 4-4, along with previously calculated models (B [4] and C [77]) along with an 
arylpiperazine ligand. 
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Table 4-7 Compounds used for the calculation of the pharmacophore hypothesis for affinity to 5-HT7 and 5-HT2a receptors. 
5-HT2a 5-HT7 
Compound Name Structure Compound Name Structure 
AR03 
N
NN
Me
ON
Me  
10a 
N
NN
ONH  
AR09 
N
NN
ON
Me
CF
3
 
AR05 
N
NN
SN
Me
Cl
 
AR13 
N
NN
n-Bu
ON
Me  
10c 
N
NN
ON
n-Pr  
AR30 
N
NN
Et
ON
Me  
AR03 
N
NN
Me
ON
Me  
E1712 N
NN
ON
Me
O
 
AR02 
N
NN
ON
Me  
JS41 
N
NN
ON
Me  
AR09 
N
NN
ON
Me
CF
3
 
AR02 
N
NN
ON
Me  
AR13 
N
NN
n-Bu
ON
Me  
10a 
N
NN
ONH  
AR30 
N
NN
Et
ON
Me  
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Table 4-7, continued. 
AB-B51 
N
N
ON
Me  
E1572 
N
N
Me
ON
Me  
14d N
N
Me
O
 
JS41 
N
NN
ON
Me  
- - AB-B68 NN
ON
Me  
Comparisons between these models and the calculated pharmacophore allows for the regions 
within each synthesized ligand to be associated with a specific binding site interaction.  A recent model 
for 5-HT7 receptor antagonism (Figure 4-4, C) describes six major binding site interactions.  The same 
naming conventions as in section 2.2.4 are used to describe binding site interactions.  Docking 
experiments28 using homology models of the 5-HT7 receptor and arylpiperazines have shown that these 
compounds bind to the 5-HT7 receptor by forming a salt bridge with Asp 3.32 and participating in 
interactions with Phe 6.51, Phe 6.52 and Ser 5.42 [77]. Although the size of the synthesized ligands 
allows for the ability to bind in either of two binding pockets, analysis of the models leads us to conclude 
that these arylpiperazines must bind in an analogous manner as previous ligands. The problem of 
multiple binding modes can be addressed by examining the distances between the regions.  It is possible 
that the pyrimidine region of these smaller ligands interacts with either the HYD/AR1 or HYD/AR2 region 
in the previous models as the distance between these two regions and the central PA is virtually 
identical (Table 4-8).  The synthesized pyrimidines are assumed to bind in a similar manner as previous 
arylpiperazines.  In addition to multiple binding modes, care must be taken not to place unwarranted 
confidence in absolute positions of calculated regions which are result from the analysis of arbitrary 
                                                          
28
 docking – in this case, docking refers to molecular modeling methods which can be used to predict the binding 
mode of ligands; docking studies find the best fit for known ligands within a binding site, according to their 
minimized interactions with the receptor 
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conformations.  Examples of this from the database include structures containing N-piperazino 
substituents or alkyl substituents to the central aromatic ring and have been outlined in detail in the 
previous sections.   
The calculated pharmacophore shows the presence of a protonated amine (PA), two hydrophobic or 
aromatic regions (HYD/AR), and a hydrogen bond acceptor (HBA).  Compound AR13 is shown overlaying 
the proposed pharmacophore.  From the observations above, it is assumed that the protonated amine 
region seen in each model is represented by the basic nitrogen in the piperazine ring.  The pyrimidine 
ring likely corresponds to the hydrophobic/aromatic region seen in all models at about 5.5 angstroms 
from the protonated amine.  The nitrogen of the pyrimidine ring may interact with Ser 5.42 in the same 
manner as has been proposed for similar arylpiperazines.  Substituents to the pyrimdine ring may affect 
the interaction with Ser 5.42 (as in furyl substituents) or with Phe 6.51 and Phe 6.52.  It is also possible 
that these substituents interact with a region which has not been previously described.  The mechanism 
by which these substituted pyrimidines affect affinity to the 5-HT7 receptor is examined in the QSAR 
study. 
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Figure 4-4.  Models calculated for antagonism of 5-HT7 including an arylpiperazine ligand.  Model A was calculated from the 
current set of compounds.  Models B [4] and C [77] were calculated in previous studies which considered a diverse set of 
compounds containing many classes of 5-HT7 ligands.  Regions of favorable interactions are characterized as being hydrogen 
bond acceptors (HBA), hydrophobic/aromatic (HYD/AR), or protonated amines (PA). 
Table 4-8. A list of calculated distances between proposed binding interactions. 
 
 
 
 
 
 
  
Regions Model A Model B Model C 
PA – HYD 1 4.6 - 6.2 5.4 - 6.4 4.3 - 7.8 
PA – HYD 2 4.3 - 5.9 5.2 – 6.2 3.7 - 6.1 
PA – HBA1 N/A 5.6 – 6.6 3.7 - 5.1 
HYD 1 – HYD 2 3.5 - 4.7 9.3 – 10.3 4.1 - 4.8 
65 
 
 
 
4.2.2 The model for affinity to the 5-HT7 receptor  
A total of 60 compounds had experimental data available to calculate a CoMSIA model for affinity to 
the 5-HT7 receptor.  These compounds were aligned and loaded into a molecular spreadsheet in SYBYL, 
as detailed earlier.  CoMSIA columns for steric, electrostatic, hydrogen bond acceptor, and hydrophobic 
characteristics were calculated from within SYBYL’s QSAR module.  No hydrogen bond donor fields were 
calculated as no structures in the database exhibited this characteristic and previous research has not 
described the presence of any hydrogen bond donor regions in previous pharmacophores or QSAR 
studies.  A leave-one-out (LOO) cross-validated PLS was performed and the residuals of the graph of 
experimental vs. predicted pKi were graphed.  The graph revealed four outliers far away from the 
prediction of the PLS regression.  These compounds (JS06, GD02, AB-B51, and NB45) were omitted from 
the calculated model in order to increase the predictivity of the model.  These outliers all have similar 
structural features which make them difficult to be described by the calculated function.  JS06 contains 
a furyl substituent which cannot adopt a planar arrangement with the central aromatic ring due to a 
bulky methyl group.  This interaction likely disrupts any interaction in the same way as SB14, which was 
also excluded from the analysis.  GD02 showed a high residual despite following general trends seen in 
the resulting model.  This is assumed to be due to the larger than optimal substituents at each position 
around the central ring.  Similarly, compounds AB-B51 and NB45 follow the general trends of the 
calculated model, but are omitted due to high residuals.  
In order to externally validate any model, it is common to divide the data set into training and test 
sets.  This helps to ensure a predictive model outside of cross-validated r2 stats which have been shown 
to be inconclusive when considered alone.  Hierarchial clustering has been shown to produce a more 
predictive test set.  By grouping the structures together according to their structural features, more 
diverse training and test sets can be constructed.  Using the hierarchial clustering feature available in 
SYBYL, the remaining 56 structures were split into four main groups according to the calculated 
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dendogram shown in Fig 4-4.  A test set was selected by choosing approximately 25% of the compounds 
from each group.  The training set and test set used to calculate this model is shown in Table 4-9. 
 
Figure 4-5 Dendrogram of the hierarchial clustering of all 56 structures used to calculate the model for affinity to the 5-HT7 
receptor.  The compounds were split into four groups (shown as different colors) based on the similarity of their structural 
features. 
A PLS crossvalidated (LOO) run was performed on the trainging set of 43 compounds in order to 
determine the optimal number of principal components (N).  It was found that at 3 components, q2 was 
at a maximum of 0.530 corresponding to a minimum predicted residual sum of squares (PRESS) of 0.690.  
The number of principal components was set at three for the following nonvalidated PLS calculation.  
The resulting calculated model is deemed significantly predictive and is summarized in Table 4-10 below. 
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Figure 4-6.  These graphs show the correlation between predicted pKi  and experimental pKi of the training set (top) and test 
set (bottom).  The pKi of these compounds was predicted by the model calculated for affinity to the 5-HT7 receptor. 
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Table 4-9.  The tables above list the predicted pKi and the experimental pKi to the 5-HT7 receptor, along with the residual. 
Training 
Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual 
Training 
Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual 
AB-B47 7.13 6.89 0.24 E1583 6.93 7.47 -0.54 
AB-B48 7.10 6.77 0.33 E1668 6.86 6.83 0.03 
AB-B67 6.40 6.17 0.23 E1712 6.47 6.78 -0.31 
AB-B73 5.95 5.74 0.21 E1756 5.66 5.78 -0.12 
AR01 6.89 7.10 -0.22 GD01 7.08 6.72 0.36 
AR02 8.14 7.48 0.66 J021 6.69 6.11 0.58 
AR03 8.41 8.16 0.25 J0222 5.44 5.68 -0.24 
AR05 8.54 8.27 0.27 J027 5.64 5.89 -0.25 
AR10 7.66 8.10 -0.44 JK05 7.60 7.50 0.11 
AR13 8.80 8.36 0.43 JK06 7.89 7.51 0.38 
AR30 8.15 8.27 -0.11 JK115 7.03 7.54 -0.51 
AR43 6.00 6.17 -0.16 JK118 7.13 7.43 -0.30 
AR45 8.05 7.37 0.67 JK120 7.01 7.43 -0.42 
E1032 6.53 6.31 0.21 10j 7.31 7.47 -0.16 
E1052 6.04 5.48 0.56 JS07 5.03 5.51 -0.48 
E1262 6.58 7.10 -0.52 JS10 6.34 7.03 -0.69 
E129 6.97 7.10 -0.13 JS11 5.56 5.32 0.24 
E1352 6.51 5.95 0.56 JS17 7.92 7.85 0.08 
E1362 6.13 6.52 -0.39 JS18 6.71 6.09 0.61 
E1405 6.65 5.99 0.66 SB12 5.71 6.12 -0.42 
E149 4.76 6.04 -1.27 SS06 5.99 6.39 -0.40 
E1572 8.10 8.00 0.10     
Test Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual Test Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual 
AB-B68 7.96 6.80 1.16 JK04 8.10 7.55 0.55 
AB-B72 6.51 5.67 0.84 JK119 7.08 7.49 -0.41 
AR09 8.08 8.40 -0.32 JS02 5.37 5.90 -0.53 
AR39 6.83 5.77 1.06 JS41 8.48 8.29 0.20 
E134 6.13 6.02 0.11 JS49 7.74 7.93 -0.19 
E178 6.68 6.65 0.03 LS104 6.20 6.90 -0.70 
J0212 5.33 5.77 -0.44     
  
69 
 
 
 
Table 4-10. The statistics relating to the validity and predicitivity of the model for affinity to the 5-HT7 receptor are shown. 
 5-HT7 Model 
q2 0.530 
Size of dataset 43 
#/N 19 
r2 0.800 
F-value 52.0 
Standard Error 0.45 
 
Further validation of the model comes from evaluating the test set predicted pKi.  All compounds fall 
within a reasonable range of error based on the error in the measurement.  Prediction for compounds 
AB-B68 and AR39 are the only compounds that are off by more than a factor of magnitude.  In the 
calculated residuals show that for all structures except AB-B68 and AR39, the predicted pKi is within 1 of 
the experimental value.  This suggests that most error in the model comes from the artificial tilt of the 
piperazine ring present in the minimized structures of benzenes and pyridines, as well as 
homopiperazines such as AR39. 
4.2.3 Calculation of a model for affinity to the 5-HT2a receptor 
The model for affinity to the 5-HT2a receptor was calculated by the same procedures as for the 5-HT7 
receptor.  Less experimental data was available for the 5-HT2a receptor, so only 50 compounds were able 
to be analyzed initially. After a PLS analysis which showed reasonable predictivity, the residuals of this 
group were plotted and the compounds that deviated the most were excluded from the subsequent 
model calculation.  These 5 compounds were JS41, E178, E149, 10j, and JS17.  Compounds 10j and E149 
did not align well to the common template with respect to large substituents.  While these compounds 
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provided increased diversity to the calculated model, the inconsistencies with alignment of the side 
chains led to large residuals in the non-crossvalidated analysis. 
The remaining 45 compounds were analyzed by hierarchical clustering as outlined in the previous 
section and split into four groups according to their structural features. The dendrogram is shown 
below.  These structures were split into a training set and a test set as before. 
 
 
Figure 4-7.  Dendrogram of the hierarchical clustering of all 45 structures used to calculate the model for affinity to the 5-HT2a 
receptor.  The compounds were split into four groups (shown as different colors) based on the similarity of their structural 
features. 
A PLS crossvalidated (LOO) run was performed on the training set of 35 compounds and the optimum 
number of components was determined to be 4 which corresponds to a minimum PRESS and a q2 of 
0.683.  The subsequent PLS analysis yielded a statistically significant model and is summarized in Table 
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4-.  The model is further supported by a strong correlation between the test set experimental and 
predicted pKi. 
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Figure 4-8.  These graphs show the correlation between predicted pKi and experimental pKi of the training set (top) and test 
set (bottom).  The pKi of these compounds was predicted by the model calculated for affinity to the 5-HT2a receptor. 
5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
AR13
AR30
AR02
AR03
E1712
E1572
E1405
E129
J0212
AB-B48
E134
E1583
GD01
J021
AB-B67
AR05
AB-B68
NB45
E1362
LS104
AR39
E1032
E1668
SS06
JS10
AB-B47
JK118
E1756
E1352
JK120
JS11
E149
JS02
AB-B73
JK122
f(x) = 0.81x + 1.28
R² = 0.78
Training set affinity for the 5-HT2a receptor
(predicted vs. experimental)
Experimental pKi
P
re
d
ic
te
d
 p
K
i
5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
AB51
AB72
AR09
AR45
E1052
E1262
J027
JK03
JK115
JK119
f(x) = 0.63x + 2.39
R² = 0.74
Test set affinity for the 5-HT2a receptor
(predicted vs. experimental)
Experimental pKi
P
re
d
ic
te
d
 p
K
i
73 
 
 
 
Table 4-11.  The tables above list the predicted pKi and the experimental pKi to the 5-HT2a receptor, along with the residual. 
Training 
Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual 
Training 
Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual 
AR13 8.72 8.16 0.57 E1362 6.71 6.88 -0.18 
AR30 7.92 7.73 0.19 LS104 6.68 6.45 0.23 
AR02 7.70 7.22 0.48 AR39 6.50 6.46 0.04 
AR03 7.66 7.51 0.14 E1032 6.48 6.29 0.19 
E1712 7.48 7.27 0.22 E1668 6.35 6.53 -0.18 
E1572 7.21 7.43 -0.22 SS06 6.25 6.11 0.14 
E1405 7.17 7.43 -0.26 JS10 6.21 6.76 -0.55 
E129 7.17 7.60 -0.43 AB-B47 6.17 6.36 -0.19 
J0212 7.08 7.05 0.03 JK118 6.11 6.13 -0.02 
AB-B48 7.05 7.04 0.01 E1756 6.07 5.92 0.15 
E134 6.97 6.57 0.40 E1352 6.04 6.20 -0.16 
E1583 6.94 6.92 0.02 JK120 5.99 5.98 0.01 
GD01 6.87 6.74 0.13 JS11 5.95 6.01 -0.06 
J021 6.84 6.94 -0.10 
    
AB-B67 6.82 6.61 0.21 JS02 5.72 5.72 -0.01 
AR05 6.80 7.22 -0.42 AB-B73 5.71 5.51 0.20 
AB-B68 6.79 6.60 0.19 JK122 5.16 5.23 -0.07 
NB45 6.72 6.97 -0.25 
    
Test Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual Test Set 
pKi 
(Exp.) 
pKi 
(pred.) 
Residual 
AB-B51 7.39 7.33 0.06 E1262 7.34 7.32 0.02 
AB-B72 6.48 6.30 0.19 J027 7.46 6.67 0.79 
AR09 8.11 7.71 0.40 JK03 5.94 6.47 -0.53 
AR45 7.85 7.20 0.65 JK115 6.82 6.42 0.41 
E1052 6.19 5.80 0.38 JK119 5.58 6.12 -0.54 
Table 4-12.  The statistics relating to the validity and predictivity of the model for affinity to the 5-HT2a receptor are shown. 
 5-HT2a Model 
q2 0.683 
Size of dataset 35 
#/N 4 
r2 0.864 
F-value 47.8 
Standard Error 0.28 
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4.3 Analysis of each set of compounds according to the calculated models 
As was outlined in the introduction, it is the goal of this research to synthesize novel, selective 5-HT7 
receptor ligands.  A large library of compounds which show high affinity to the receptor has been 
synthesized and QSAR models have been calculated which detail the requirements for binding to the 5-
HT7 receptor and to the receptor which has the most similar binding profile, the 5-HT2a receptor.  By 
examining the differences between these two models, information pertaining to increasing the 
selectivity of ligands over the 5-HT2a receptor can be gained.  Each subset of synthesized ligands has 
been analyzed using the QSAR models to provide ways of increasing affinity and selectivity.  These 
models are shown below in Figure 4-9 through 4-13. 
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Figure 4-9. The calculated CoMSIA models for binding affinity to 5-HT7 (top) and 5-HT2a (bottom).  Favored and disfavored 
regions of steric bulk (green/yellow), electrostatic charge (red/blue), hydrophobicity (orange/grey), and hydrogen bond 
acceptors (magenta/cyan) describe the binding site interactions with these ligands. 
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4.3.1 Steric interactions 
 
Figure 4-10. Contours of favored and disfavored steric interactions to both the 5-HT7 and 5-HT2a receptors. 
The steric interactions as calculated are shown in Figure 4-10 above.  The major region of 
interest surrounds the alkyl substituents to the pyrimidine ring.  This region of favorable interaction is 
larger in the model for affinity to the 5-HT2a receptor.  This difference is likely due to the drastic increase 
in affinity exhibited by compounds with an n-hexyl substituent at this position, such as JS41.  This region 
of the ligands likely binds with the alkyl group near the hydrogen bond acceptor Ser 5.42.  Due to the 
diversity of the synthesized compounds with respect to steric properties of substituents in this region, 
this interaction does not appear to offer any selectivity advantages by further optimization.  Also seen 
are disfavored regions surrounding furyl substituents in both models.  This leads to the conclusion that 
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this region will also not allow for any further optimizations, as the furyl substituent is a relatively small 
aromatic substituent and increases in size are not advantageous. 
4.3.2 Electrostatic Interactions 
The electrostatic interactions, displayed in Figure 4-11 show two areas of interest, corresponding with 
the furyl substituents and the protonated amine of piperazine substituents.  The fields surrounding furyl 
substituents are likely a result of the large difference in affinity observed between 4-(2-furyl)pyrimidines 
and 4-(3-furyl)-pyrimidines, as discussed earlier.  This difference (two orders of magnitude) results in 
sharply defined fields in both models which result in favored electrostatic interactions corresponding 
with the 2-furyl analogs and regions of disfavored interactions corresponding with 3-furyl analogs.   In 
the model for affinity to the 5-HT7 receptor, there is an additional region near the protonated amine.  
This disfavored interaction results from the decreased affinity of homopiperazine compounds which 
were aligned with the protonated amine centered over this disfavored region.  The decrease in affinity 
also results in disfavored hydrophobic interactions as is discussed later. 
The calculated models show limited opportunities for further optimizations with regard to electrostatic 
modifications.  The calculated regions in each model are largely identical, although the homopiperazine 
moiety seems to be tolerated better by the 5-HT7 receptor.  Shortening the distance between the 
central aromatic ring and the protonated amine, or constraining the amine to one side of the central 
ring are possible ways to increase the selectivity of future ligands. 
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Figure 4-1. Contours of favored and disfavored electrostatic interactions to both the 5-HT7 and 5-HT2a receptors. 
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4.3.3 Hydrophobic interactions 
 
Figure 4-2. Contours of favored and disfavored hydrophobic interactions to both the 5-HT7 and 5-HT2a receptors. 
Hydrophobic interactions were the most prevalent CoMSIA field calculated in both models.  The most 
interesting of these hydrophobic regions is the large disfavored region surrounding N-substituents of 
piperazine compounds.  This large grey region is seen only in the model for affinity to 5-HT2a.  
Compounds such as JK118 which exploit this region by including a benzyl moiety show higher affinity to 
the 5-HT7 receptor, although within the experimental error.  This disfavored region provides an excellent 
lead for further modifications in this region.   
Also shown is the disfavored region corresponding to the homopiperazine moiety mentioned earlier, in 
the model for affinity to the 5-HT7 receptor.  This region supports the presence of the disfavored 
electrostatic region observed previously.  Regions of favored hydrophobic interactions correspond with 
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the furyl ring which supports the qualitative assumptions made previously about the interaction with 
this group and phenylalanine residues of the binding site.  Other small favored regions exist around the 
alkyl substituents, but no differences are observed that can be exploited for increasing affinity or 
selectivity  of ligands to either receptor.  
 
4.3.4 Hydrogen bond donor interactions 
 
 
Figure 4-3. Contours of favored and disfavored hydrogen bond acceptor interactions to both the 5-HT7 and 5-HT2a receptors. 
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There are typically regions in each compound which contain a hydrogen bond acceptor.  These 
correspond to the oxygen in furyl substituents, each nitrogen in pyrimidine (or pyridine), and each 
nitrogen in piperazine.  The most crucial of these hydrogen bond acceptors is the protonated amine, 
which has been shown to form a salt bridge with Asp 3.32 in the central binding site region.  The models 
do not represent this well, although the database of structures were not protonated.  A large disfavored 
region is observed in the model for affinity to the 5-HT7 receptor, which again may be representative of 
the disfavored interaction of the homopiperazine moiety.  Regions also exist around the the furyl 
substituent of the compound shown, also likely due to disfavored interactions of 4-(2-furyl)pyrimidines.  
These interactions have already been attributed to the enhanced ability of 4-(3-furyl)pyrimidines to 
rotate with respect to the torsion angle between the aromatic rings. 
The most interesting regions described by hydrogen bond acceptor interactions are those surrounding 
the central aromatic ring.  A series of pyridines and benzenes allows for the comparison of the necessity 
of each nitrogen in pyrimidine ligands. It is observed that a favored hydrogen bond acceptor interaction 
is calculated at the nitrogen near alkyl substituents, or away from aromatic substituents.  This 
observation provides additional support for the interaction between substituents to the opposite side of 
the pyrimidine ring and phenylalanine residues in the binding site.  This favored interaction may 
therefore correspond to Ser 5.42 in the binding site.  This would allow for further optimization of this 
region of the 5-HT7 pharmacophore with respect to affinity and selectivity over 5-HT2a. 
 
82 
 
 
 
5 CONCLUSIONS 
Several potential therapeutic applications exist for selective 5-HT ligands.  This potential has not been 
completely defined or exploited.  This is partially due to the unavailability of potent and selective 5-HT 
ligands.  This is particularly true with the 5-HT7 receptor, as it is the most recently characterized of the 5-
HT receptor subtypes.  Hundreds of novel 5-HT7 ligands have been synthesized at Georgia State 
University in order to address this need.  These compounds were optimized based on previous research 
and have yielded ligands with greater potency and selectivity to the 5-HT7 receptor, with respect to 5-
HT2a. The 5-HT7 binding site has been explored with analogs by both qualitative and quantitative means, 
resulting in a better understanding of the receptor structure.   
In synthesizing new 5-HT7 receptor ligands, systematic substitutions of pyrimidines were examined.  The 
substituents of pyrimidine ligands were optimized by adding diverse substituents to the aromatic ring.  
Several different synthetic pathways were described to yield novel substituted pyrimidines.  These 
include the nucleophilic addition to pyrimidine as previously described.  These additions included highly 
functionalizable groups which underwent subsequent modifications allowing more many diverse 
substitutions.  This was the case for 1,4 addition to 4-vinylpyrimidines as well as hydrolysis of 1-ethoxy-
1-ethenyl substituents.  These compounds were used as starting material for the synthesis of several 
diverse 5-HT7 receptor ligands.  Evaluation of these ligands revealed a ligand with high potency and 
selectivity to the 5-HT7 receptor, AR13. This ligand was used as a scaffold to investigate other proposed 
binding site interactions.   
The region corresponding to the linker between the two binding pockets of the receptor was explored 
by altering the piperazino substituents.  The presence of a steric group extending past the piperazino 
protonated amine was shown to be well tolerated by the 5-HT7 receptor.  Bulky groups, such as the 
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benzyl analogs synthesized, were not well tolerated by the 5-HT2a receptor which led to a significant 
selectivity advantages. 
The synthesized pyrimidines and benzofurans, along with other pyridines and benzenes were analyzed 
by 3D-QSAR methods to yield models for affinity to 5-HT7 and 5-HT2a.  These models clearly describe the 
observations noted above and detail pharmacohphore regions of these receptors.  These two models 
have been compared to find that two significant regions of steric interactions differ significantly 
between the two models.  These relationships have not been previously described and will lead to more 
potent and selective ligands.  These ligands will allow for further physiological studies and possibly lead 
to therapeutics. 
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6 EXPERIMENTAL 
Equipment: 
All reagents were purchased from Aldrich Chemical Company or prepared according to the literature.  
Compounds prepared by others under the direction of Dr. Strekowski include 3b, 6d-k, 6m-n, 10a, and 
10l.  Reactions were monitored by TLC (EMD Chemicals, TLC Silica Gel 60 F254) or GCMS (Shimadzu GC-
17A, QP-5000 MS).  All purifications were performed on a Chromatotron (Harrison Research, Model 
7924T).  Solid samples were subjected to melting point analysis (Barnestead International, Mel-Temp 
1201D).  All samples sent for biological testing were converted to salts by the procedure outlined below 
and analyzed for elemental composition (Perkin Elmer, 2400 Series II) to ensure purity.  NMR data was 
acquired using the Bruker Avance 400 MHz NMR spectrometer.  NMR data was processed using 
TOPSPIN v.3.0.b.8 software (Bruker).  All NMR spectra were obtained in deuterated chloroform at room 
temperature.   Experimental affinity to 5-HT receptors was determined in a separate lab by the 
procedure outlined by below.  All samples sent for biological testing were converted to salts and 
analyzed for elemental composition (Perkin Elmer, 2400 Series II) to ensure purity. 
Biological evaluation: 
All biological evaluation was determined through collaboration with Dr. Andrzej Bojarski in The Institute 
of Pharmacology at the Polish Academy of Sciences.  Below are details of the analyses as described by 
Dr. Bojarski. 
In vitro radioligand binding assays:  Inhibition constants (Ki) were determined from at least three 
separate experiments in which 7–9 drug concentrations, run in triplicate, were used (SEM ± 20%). The 
binding reaction was terminated by rapid filtration through Whatman GF/B filters followed by three 4-
ml washes with ice-cold incubation buffer.  
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The radioactivity retained on the filters was measured by liquid scintillation counting (Beckman LS 6500 
apparatus) in 4 ml scintillation fluid (Akwascynt, BioCare). Binding isotherms of the tested compounds 
were analyzed by non-linear regression (Prism, GrafPad Software Inc., San Diego), using the Cheng-
Prusoff equation [132] to calculate Ki values. 
5-HT1A, 5-HT2A, dopamine D2 and 1-adrenergic receptor binding assay:  Radioligand studies with native 
5-HT1A, 5-HT2A, D2 and 1-adrenergic receptors were conducted according to the methods previously 
described [116,133,134]. Briefly: 5-HT1A assays used rat hippocampal membranes, [
3H]-8-OH-DPAT (106 
Ci/mmol, Perkin-Elmer) and 5-HT for nonspecific binding; 5-HT2A assays used rat cortical membranes, 
[3H]-ketanserin (67 Ci/mmol, Perkin-Elmer) and methysergide for nonspecific binding; dopamine D2 
assays used rat striatal membranes, [3H]-spiperone (15.0 Ci/mmol, Perkin-Elmer) and butaclamol for 
nonspecific binding; 1 assays used rat cortical membranes, [
3H]-Prazosine (25.0 Ci/mmol, Amersham) 
and phentolamine for non-specific binding. 
Expression of the gene for the human 5-HT7(b) receptor:  The full length human 5-HTR7(b) cDNA cloned 
into mammalian expression vector pcDNA3.1(+) was purchased from UMR cDNA Resource Center 
(www.cdna.org).  The receptor cDNA was stably transfected into human embryonic kidney cells 
(HEK293, ATCC) with use of Lipofectamine 2000 (Invitrogen).  A clone yielding high expression level of 5-
HTR7(b) was selected during preliminary experiments including Western Blot analysis, [
3H]-CT saturation 
binding studies as well as cAMP accumulation assays. 
Cell culture and preparation of cell membranes:  HEK293 cells with stable expression of 5-HTR7(b) were 
maintained at 37 °C in a humidified atmosphere with 5% CO2 and were grown in Dulbeco’s Modifier 
Eagle Medium (Gibco BRL) containing 5% dialysed foetal bovine serum (Gibco BRL) and 500 g/ml G418 
sulphate (Sigma-Aldrich). For membranes preparations, cells were subcultured in 10 cm diameter dishes, 
grown to 90% confluence, washed twice with prewarmed to 37 °C phosphate buffered saline and 
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pelleted by centrifugation (1000 g) in phosphate buffered saline containing 0.1 mM EDTA and 1 mM 
dithiothreitol. Prior to membrane preparations pellets were stored at –80 °C. 
Membranes were prepared form frozen cell pellets by homogenization (Polytron, setting 5 for 15 s) and 
centrifugation (50,000 g, 15 min., 4ºC) in 20 volumes of Tris HCl buffer (50 mM, pH 7.4) containing EDTA 
(0.1 mM). The pellets were then re-suspended in buffer, incubated 20 min. in 37 °C and once again 
centrifuged as described above. The membranes were stored in aliquots at –80 °C until use for binding 
assays. 
The protein concentration was determined with bicinchoninic acid protein assay kit (Pierce, USA). 
5-HT7 receptor binding assay:  Binding assays on membranes from HEK 293 cells stably expressing 
human 5-HT7(b) receptor were performed according to procedure described by Thomas et al. [135].  
Briefly, the membranes (10 g protein per tube) were incubated in 50 mM Tris HCl buffer (pH 7.4) 
containing 4 mM MgCl2, 0.1 mM pargyline and 0.1% ascorbic acid, in the presence of 7–9 concentrations 
of test drug and 0.5 nM [3H]-5-CT (93.0 Ci/mmol, Amersham). Nonspecific binding was defined in the 
presence of 10 M of 5-HT.  After a 1-h incubation at 37 °C, the assay samples were rapidly filtered 
through Whatman GF/B filters and subsequently washed with ice-cold 50 mM Tris buffer (pH 7.4) using 
a Brandel harvester. 
Computer methods: 
Conformational analysis:  Structures were drawn in their s-cis conformation using HyperChem 8.0 
(Hypercube, Inc.).  Each structure was imported into Spartan ’04 (Wavefunction, Inc.) and minimized 
using the MMFF force field.  The torsion angle consisting of N3-C4-C7-C8 was set to 0 degrees.  A 
dynamic constraint was applied to this torsion angle ranging from 0 to 350 degrees in 36 steps, resulting 
in a stepwise rotation of 10 degrees.  An ab initio Hartree-Fock calculation was performed using the 6-
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31G* basis set.  The calculated energy of the structure corresponding to a global minimum was set to 0 
kcal/mol and energies for all other torsions were reported relative to the global minimum.  
Calculation of pharmacophore model:  Structures exhibiting high affinity (top 20%, by pKi) to the 
receptor in question were chosen from the database of aligned structures to each receptor.  The highest 
affinity compound was conformed analogous to the total set of structures.  All structures were then 
aligned by features to the template using the GALAHAD module in Sybyl (Tripos, Inc.), using the 
parameters suggested.  The best calculated model was chosen as the model which fit the highest 
percentage of compounds from the original dataset. 
Calculation of 3D-QSAR models:  A database of aligned structures with corresponding experimental 
data was loaded into a Sybyl molecular spreadsheet.  The structures were represented in the moleculsr 
spreadsheet by calculating CoMSIA fields for steric, electrostatic, hydrophobic, and hydrogen bond 
acceptor interactions.  Internal validation was conducted by leave-one-out crossvalidation.  The SAMPLS 
method (Merck & Co., Inc.) was used in order to minimize computational time.  A non-crossvalidated 
partial least squares analysis was calculated using the optimal number of components (least number of 
components which did not observe > 5% decrease in predicted error).  The QSAR model was presented 
with favorable contours at 80% of the total contribution and disfavorable contours at 10% of the 
contribution. 
Synthesis: 
Conversion to salts:  The appropriate compound was dissolved in diethyl ether:methanol (3 mL, 10:1) 
before the addition of HBr (0.2 mL, 48%) or HCl (0.2 mL, 38%).  The solution showed evidence of 
precipitant before the addition of more diethyl ether (20 mL).  The additional ether precipitated the 
compound as the corresponding salt. 
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Preparation of organolithium reagents. Alkyllithium reagents n-butyllithium (2.5 M in hexanes), tert-
butyllithium (1.7 M in pentane), and sec-butyllithium (1.4 M in cyclohexane) were commercial reagents.  
All other organolithium reagents were generated in situ and used without characterization.  
3-lithio furan was generated as described in the literature [136].  In summary, a solution of 3-
bromofuran (0.33 mL, 3.7 mmol) in tetrahydrofuran (3 mL) was treated dropwise at -78˚C with n-
butyllithium (1.5 mL, 3.7 mmol).  The solution was stirred for an additional 10 min at -78˚C before use.  
2-lithiofuran was prepared in a similar manner by treatment of a solution of furan (2.18 mL, 24.7 mmol) 
with n-butyllithium (4.0 mL, 10.0 mmol). 2-lithio-4,5-dihydrofuran was also generated in this manner by 
treating a solution of 2,3-dihydrofuran (0.23 mL, 3.0 mmol) in tetrahydrofuran (3 mL) with tert-
butyllithium (1.8 mL, 3.0 mmol). .Ethoxyvinyl lithium was prepared according to the literature [137], by 
treating a solution of ethyl vinyl ether (0.49 g, 6.8 mmol) in tetrahydrofuran (3 mL) with tert-butyllithium 
(2.0 mL, 3.4 mmol) at -78˚C.  The bright yellow solution was stirred at 0˚C for 10 min.  The reagent was 
cooled to -78˚C after the solution had become colorless for immediate use.  Vinyllithium was generated 
as described [94,138], by treatment of a solution of tetravinyltin (0.98 mL, 5.1 mmol) in tetrahydrofuran 
(3 mL) with tert-butyllithium (2.4 mL, 4.1 mmol) at -78˚C.  The solution was stirred for 10 min until the 
formation of a white precipitant was evident. α-lithiostyrene was generated by dropwise addition of n-
butyllithium (1.2 mL, 3.0 mmol) to a solution of α-bromostyrene (0.43 mL, 3.0 mmol) in tetrahydrofuran 
(3 mL) at -78˚C.  The resulting deep red mixture was used immediately. 
General procedures for 3a-f, and 4a-g [13]. 2-chloropyrimidine (1a), 2-chloro-5-fluoropyrimidine (1b) 
and 2,4-dichloropyrimidine (1c) were purchased from Aldrich Chemical Company.  A solution of the 
appropriate organolithium reagent (3.0 mmol) was generated as described above.  Dropwise addition of 
2-chloropyrimidine 1 (3.0 mmol) dissolved in a minimum amount of anhydrous THF caused the solution 
to darken to black with a green tint over the course of the addition.  The flask was slowly warmed to -
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40˚C over a period of 1 hour, and then stirred at -40˚C for an additional three hours. The reaction was 
then quenched by the dropwise addition of deionized water (0.1 ml, 6 mmol) dissolved in THF (5 ml).  
The mixture was stirred at 20˚C for 10 min, resulting in a pale orange solution with white precipitate 
(LiOH).  To this mixture was added 2,3-dichloro-2,3-dicyanoquinone (DDQ, 0.68 g, 3.0 mmol) dissolved in 
THF (5 ml).  The solution was stirred for 2 min before the addition of 3M NaOH (20 ml).  The solution 
was extracted with hexanes (20 ml) and hexanes:THF (20 ml, 1:1) and the extract was dried over 
magnesium sulfate, filtered and concentrated under reduced pressure.  The resulting residue was 
purified qualitatively to yield the 4-substituted 2-chloropyrimidines 4, which were subsequently used in 
the reaction with N-methylpiperazine.  A flask dried as before was charged with 3 (1.0 mmol) and dry 
toluene (3 ml).  To the solution was added an excess of an appropriate piperazine (3.0 mmol) and the 
solution was heated at 110˚C for 1 day.  The reaction was monitored by TLC, and after the reaction had 
gone to completion (by absence of starting material), the solution was made basic with 2M sodium 
carbonate (10 ml).  The resulting solution was extracted with diethyl ether (3 X 20 ml).  The organic 
layers were combined, dried over magnesium sulfate, filtered and concentrated under reduced pressure 
before purification by chromatography (dichloromethane:methanol, 10:1) yielded the piperazine 
derivatives 4 as yellow oil. 
4-tert-Butyl-2-chloropyrimidine (3a). This compound was prepared using minor variations to the 
general procedure.  The addition of tert-butyllithium occurred at -40˚C, and was then allowed to reach 
0˚C over 1 hour.  Purification using a mobile phase of hexanes:dichloromethane (2:1) yielded 3a (0.223 
g, 1.3 mmol, 44%) as a white solid.  Characterization matches that previously reported.  1H NMR (400 
MHz, CDCl3) δ 8.51 (d, J = 5.1 Hz, 1H), 7.26 (d, J = 5.1 Hz, 1H), 1.35 (s, 9H).  
13C NMR (100 MHz, CDCl3) δ 
181.8, 161.1, 159.4, 115.3, 37.9, 29.2. 
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2-Chloro-4-(3-furyl)pyrimidine (3b). This compound was obtained in 57% yield as a white solid:  mp 88-
89˚C.  Characterization correlated with that previously recorded (publication in writing).  1H NMR (400 
MHz, CDCl3) δ 8.55 (d, J = 5.1 Hz, 1H), 8.22 (m, 1H), 7.54 (m, 1H), 7.31 (d, J = 5.1 Hz, 1H), 6.91 (m, 1H). 
2-Chloro-4-(1-ethoxy-1-ethenyl)pyrimidine (3c). This compound was obtained in 40% yield as a white 
solid. Characterization correlated with that previously recorded (publication in writing).  1H NMR (400 
MHz, CDCl3) δ 8.61 (d, J = 5.1 Hz, 1H), 7.57 (d, J = 5.1 Hz, 1H), 5.73 (d, J = 2.4 Hz, 1H), 4.57 (d, J = 2.4 Hz, 
1H),  3.97 (q, J = 7.0 Hz, 2H), 1.44 (t, J = 7.0 Hz, 3H). 
2-Chloro-4-vinylpyrimidine (3d).  This compound was synthesized using a modification of the general 
procedure.  Addition of 2-chloropyrimidine to a mixture of vinyllithium at -78 °C caused the solution to 
darken, eventually turning black.  The reaction was allowed to reach -60 °C over 1 hour before 
quenching.  Workup and purification using a mobile phase of hexanes:dichloromethane (1:1) yielded 3d 
in 59% yield as a faintly yellow oil.  Characterization correlated with that previously reported [138].  1H 
NMR (400 MHz, CDCl3) δ 5.79 (d, 1H, -CH2, J=10.8 Hz), 6.54 (d, 1H, -CH2, J=17.4 Hz), 6.71 (dd, 1H, -CH, 
J=10.8, 17.4 Hz), 7.24 (d, 1H, -CH, J=5.0 Hz), 8.57 (d, 1H, -CH, J=5.0 Hz). 
2-Chloro-4-(1-phenylethenyl)pyrimidine (3e). This compound was obtained in 58% yield as a colorless 
oil.  1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.1 Hz, 1H), 7.40 (m, 3H), 7.31 (m, 2H), 7.09 (d, J = 5.1 Hz, 
1H), 6.48 (m, 1H), 5.77 (m, 1H) 13C NMR (CDCl3): δ 167.7, 161.5, 159.8, 145.9, 138.1, 128.6, 128.5, 128.4, 
123.1, 117.5.  High-resolution ms (ESI, positive ion mode): calcd. for C12H9
35ClN2 (M
++ 1), m/z 217.0533; 
found m/z 217.0526. 
2-Chloro-4-(3-furyl)-5-propylpyrimidine (3f). This compound was obtained in 17% as a crude, 
colorless oil.  The oil was used without further purification.  1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H, -CH), 
8.03 (s, 1H), 7.54 (m, 1H), 7.00 (m, 1H), 2.74 (t, J = 7.4 Hz, 2H), 1.70 (sxt, J = 7.4 Hz, 2H), 1.05 (t, J = 7.4 
Hz, 3H). 
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 4-sec-Butyl-2-(4-methylpiperazino)pyrimidine hydrobromide (4a). The free base was obtained in 32% 
yield.  1H NMR for the free base (400 MHz, CDCl3) δ 8.18 (d, J = 5.1 Hz, 1H), 6.34 (d, J = 5.1 Hz, 1H), 3.85 
(m, 4H), 2.53 (m, 2H), 2.46 (m, 4H), 2.33 (s, 3H), 1.62 (m, 1H), 1.20 (d, J = 6.8 Hz, 3H), 0.85 (t, J = 7.4 Hz, 
3H).  A hydrobromide salt:  mp 177 - 179 °C.  Anal. Calcd for C13H22N4•HBr: C, 49.53; H, 7.35; N, 17.77.  
Found: C, 49.41; H, 7.47; N, 17.47. 
4-tert-Butyl-2-(4-methylpiperazino)pyrimidine hydrobromide(4b). The free base was obtained in 52% 
yield.  1H NMR for the free base (400 MHz, CDCl3) δ 8.22 (d, J = 5.1 Hz, 1H), 6.51 (d, J = 5.1 Hz, 1H), 3.86 
(m, 4H), 2.47 (m, 4H), 2.34 (s, 3H), 1.27 (s, 9H).  13C NMR for the free base (100 MHz, CDCl3) δ 178.2, 
161.5, 157.5, 105.5, 55.1 (2 signals), 46.3, 43.7 (2 signals), 37.5, 29.3.  A hydrobromide salt:  mp 221 °C.  
Anal. Calcd for C13H22N4•HBr, ½ H2O: C, 48.15; H, 7.46; N, 17.28.  Found: C, 47.82; H, 6.92; N, 16.93. 
4-(4,5-Dihydro-2-furyl)-2-(4-methylpiperazino)pyrimidine (4c). This compound was obtained in 53% 
yield.  1H NMR (400 MHz, CDCl3) δ 8.32 (d, J=5.1 Hz, 1H), 6.66 (d, J=5.1 Hz, 1H), 5.97 (t, J = 3.0 Hz, 1H), 
4.53 (t, J = 9.7 Hz, 2H), 3.86  (m, 4H), 2.83 (dt, J = 3.0, 9.7 Hz, 2H), 2.47 (m, 4H), 2.34 (s, 3H).  13C NMR 
(100 MHz, CDCl3) δ 164.7, 158.6, 156.7, 155.5, 105.4, 103.0, 70.5, 55.0, 46.2, 43.6, 30.6. High-resolution 
ms (ESI, positive ion mode): calcd for C13H18N4O, (M
+ + 1), m/z 247.1559; found m/z 247.1562. 
2-(4-Methylpiperazino)-5-propylpyrimidine dihydrobromide (4d). The free base was obtained in 82% 
yield as an oil.  1H NMR for the free base (400 MHz, CDCl3) δ 8.16 (s, 2H), 3.81 (t, J = 4.8 Hz, 4H), 2.47 (t, J 
= 4.8 Hz, 4H), 2.40 (t, J = 7.6 Hz, 2H), 2.34 (s, 3H), 1.56 (sxt, J = 7.6 Hz, 2H), 0.93 (t, J = 7.6 Hz, 3H). A 
hydrobromide salt:  mp 251 °C (dec.).  Anal. Calcd. for C12H20N4•2 HBr: C, 37.72; H, 5.80; N, 14.66.  
Found: C, 37.87; H, 5.75; N, 14.52. 
4-(3-Furyl)-2-(4-methylpiperazino)-5-propylpyrimidine hydrobromide (4e). The free base was obtained 
in 44% yield as an oil.  1H NMR for the free base (400 MHz, CDCl3)  δ 8.17 (s, 1H), 7.91 (s, 1H), 7.48 (s, 
1H), 6.95 (s, 1H), 3.85 (m, 4H), 2.59 (t, J = 7.6 Hz, 2H), 2.49 (m, 4H), 2.35 (s, 3H), 1.59 (sxt, J = 7.6 Hz, 2H), 
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0.99 (t, J = 7.6 Hz, 3H).  A hydrobromide salt: mp 206 - 208 °C.  Anal. Calcd. for C16H22N4O•HBr: C, 52.32; 
H, 6.31; N, 15.25.  Found: C, 52.34; H, 6.11; N, 15.12. 
4-Butyl-6-(3-furyl)-2-(4-methylpiperazino)-5-propylpyrimidine dihydrobromide (4f).  The free base was 
obtained in 73% yield as an oil.  1H NMR for the free base (400 MHz, CDCl3) δ 7.80 (m, 1H), 7.47 (m, 1H), 
6.86 (m, 1H), 3.84 (m, 4H), 2.66 (m, 2H), 2.59 (m, 2H), 2.47 (m, 4H), 2.34 (s, 3H), 1.69 (m, 2H), 1.47 (m, 
4H), 1.01 (t, J = 7.6 Hz, 3H), 0.96 (t, J = 7.6 Hz, 3H).  A hydrobromide salt: mp 203 °C (dec.).  Anal. Calcd. 
for C20H30N4O •2 HBr: C, 47.63; H, 6.40; N, 11.11.  Found: C, 47.34; H, 6.65; N, 11.08. 
4-(2-Furyl)-2,4-bis-(4-methylpiperazino)pyrimidine trihydrobromide (4g). The free base was obtained 
in 37% yield as a colorless oil.  1H NMR for the free base (400 MHz, CDCl3) δ 7.47 (m, 1H), 7.05 (m, 1H), 
6.48 (m, 1H), 6.31 (s, 1H), 3.86 (m, 4H), 3.67 (m, 4H), 2.47 (m, 8H), 2.34 (s, 6H).  13C NMR for the free 
base (100 MHz, CDCl3) δ 163.4, 161.7, 155.4, 153.8, 143.2, 111.8, 109.7, 86.9, 55.2, 54.8, 46.3, 46.2, 
43.9, 43.8. A hydrobromide salt: mp 222 °C (dec.).  Anal. Calcd. for C18H26N6O•3 HBr: C, 36.95; H, 5.00; N, 
14.36.  Found: C, 37.14; H, 5.29; N, 14.62. 
General procedure for 5a-b and 6a-c, and 6l.  A procedure and characterization for compounds 5 and 6 
has been submitted for publication.  In summary, a solution of 3d or 3e (0.4 mmol) is treated with a 
prepared nucleophile (0.4 mmol).  Unless using a Grignard reagent as a nucleophile, the reaction was 
heated for 2 hours near reflux.  Grignard reagents were prepared as reported [139].  Briefly, a 
suspension of copper (I) iodide was treated with two equivalents of a carbon nucleophile at -78 °C and 
stirred for 10 min.  The Grignard reagents were then treated with 3d or 3e (0.4 mmol) at -40 °C.  After 
the addition of the pyrimidine to the nucleophile, the solution was stirred for 2 hours at -40 °C and 
quenched.  Workup and purification on a chromatotron (hexanes:dichloromethane, 4:1) yielded the 1,4-
addition products 5.  A solution of 5 (1.0 mmol) in toluene (5 mL) was then treated with N-
methylpiperazine (1.2 mmol) and stirred at reflux until the presence of 5 was no longer detectable by 
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TLC.  Purification by chromatography (dichloromethane:methanol, 10:1) yielded the substituted 
arylpiperazines 6.  Examples of 5 synthesized from nucleophiles and by Grignard reagents were 
characterized and are shown below. 
2-Chloro-4-(2-methoxy-1-phenylethyl)pyrimidine  (5a). This compound was obtained as an oil in 25% 
yield.  1H NMR (CDCl3): δ 8.47 (d, J = 5.2 Hz, 1H), 7.29 (m, 4H), 7.26 (m, 1H), 7.12 (d, J = 5.2 Hz, 1H), 4.31 
(dd, J = 8.8, 5.6 Hz, 1H), 4.20 (t, J = 8.8 Hz, 1H), 3.88 (dd, J = 8.8, 5.6 Hz, 1H), 3.35 (s, 3H);  13C NMR 
(CDCl3): δ 173.6, 161.3, 159.3, 138.4, 128.9, 128.3, 127.6, 119.5, 74.5, 59.1, 53.2.  High-resolution MS 
(ESI, positive ion mode): calcd. for C13H13
35ClN2O (M
+ + 1), m/z 249.0795; found m/z 249.0784.  
2-Chloro-4-(1,2-diphenylethyl)pyrimidine (5b). This compound was obtained in 61% yield. 1H NMR 
(CDCl3) δ 8.38 (d, J = 5.2 Hz, 1H), 7.22 (m, 9H), 7.05 (m, 2H), 7.00 (d, J = 5.2 Hz, 1H), 4.28 (dd, J = 7.4, 7.8 
Hz, 1H), 3.64 (dd, J = 7.8, 13.6 Hz, 1H), 3.30 (dd, J = 7.4, 13.6 Hz, 1H).  13C NMR (CDCl3) δ 175.0, 161.3, 
159.2, 140.7, 139.1, 129.0, 128.8, 128.3, 128.2, 127.4, 126.3, 119.1, 55.1, 40.5. High-resolution ms (ESI, 
positive ion mode): calcd. for C18H15
35ClN2, (M
+ + 1), m/z 295.1002; found m/z 295.1013. 
2-(4-Methylpiperazino)-4-(2-(4-methylpiperazino)ethyl)pyrimidine tetrahydrochloride (6a). The free 
base was obtained as an oil in 22% yield;   1H NMR for the free base (CDCl3): δ 8.17 (d, J = 5.1 Hz, 1H), 
6.38 (d, J = 5.1 Hz, 1H), 3.83 (m, 4H), 2.75 (s, 4H), 2.46 (m, 10H), 2.33 (s, 3H), 2.28 (s, 3H),  1.92 (m, 2H). A 
hydrochloride salt.  Anal. Calcd for C16H28N6•4HCl• ½ H2O: C, 41.84; H, 7.24; N, 18.30.  Found: C, 41.76; 
H, 7.10; N, 18.06.  
N-benzyl-2-(2-(4-methylpiperazino)-4-pyrimidinyl)-2-phenylethanamine (6b). This compound was 
obtained as an oil in 57% yield;  1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 5.1 Hz, 1H), 7.25 (m, 10H), 6.29 
(d, J = 5.1 Hz, 1H), 4.11 (dd, J = 6.4, 8.4Hz, 1H), 3.82 (m, 6H), 3.49 (dd, J = 8.4, 11.8Hz, 1H), 3.07 (dd, J = 
6.4, 11.8Hz, 1H), 2.45 (m, 4H), 2.34 (s, 3H);  13C NMR (100 MHz, CDCl3) δ 170.8, 161.6, 157.7, 141.1, 
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140.3, 128.6, 128.4, 128.3, 128.1, 127.0, 126.9, 109.7, 55.0, 53.9, 53.1, 53.0, 46.3, 43.7. High resolution 
ms (ESI, positive ion mode): calc’d for C24H29N5, (M
++1), m/z 388.2501, found m/z 388.2491. 
4-(2-Ethylthio)-1-phenylethyl)-2-(4-methylpiperazino)pyrimidine (6c). This compound was obtained as 
an oil in 37% yield;  1H NMR (CDCl3) δ 8.15 (d, J = 5.2 Hz, 1H), 7.29 (m, 5H), 6.34 (d, J = 5.2  Hz, 1H), 4.01 
(m, 1H), 3.88 (m, 4H), 3.48  (m, 1H), 3.06 (m, 1H), 2.48 (m, 6H), 2.35 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H);  13C 
NMR (CDCl3): δ 170.7, 161.6, 157.7, 141.7, 128.5, 128.1, 127.1, 109.4, 55.0, 53.8, 46.3, 43.7, 36.1, 26.7, 
14.8.  High-resolution ms (ESI, positive ion mode): calcd. for C19H26N4S (M
+ + 1), m/z 343.1956; found m/z 
343.1947. 
2-(4-Methylpiperazino)-4-(1-phenylpropyl)pyrimidine (6l). This compound was obtained as an oil in 
39% yield.  1H NMR (CDCl3) δ 8.13 (d, J = 5.2 Hz, 1H), 7.30 (m, 4H), 7.20 (m, 1H), 6.32 (d, J = 5.2 Hz, 1H), 
3.86 (t, J = 5.2 Hz, 4H), 3.66 (t, J = 7.6 Hz, 1H), 2.46 (t, J = 5.2 Hz, 4H), 2.34 (s, 3H), 2.23 (m, 1H), 1.99 (m, 
1H), 0.88 (t, J = 7.6 Hz, 3H);  13C NMR (CDCl3) δ 172.5, 161.7, 157.4, 142.8, 128.3, 128.2, 126.5, 109.0, 
55.4, 55.0, 46.3, 43.7, 27.5, 12.5. High-resolution ms (ESI, positive ion mode): calcd. for C18H24N4 (M + 1)
+, 
m/z 297.2079; found m/z 297.2089.  
4-Acetyl-2-chloropyrimidine (7). To 3c (0.230 g, 0.125 mmol) was added ethanol (6 mL), methanol (6 
mL), water (6 mL), and conc. HCl (2 mL).  The solution was stirred for 12 hours at 20 °C until starting 
material was no longer detected by TLC. The solution was made basic with sodium carbonate (2M, 5 mL) 
and separated with diethyl ether:hexanes (1:1, 3 X 20 mL), dried over magnesium sulfate, filtered and 
concentrated under reduced pressure.  Purification by chromatography using an eluent of 
hexanes:dichloromethane (1:1) yielded 7 (0.116 g, 0.740 mmol, 59%) as a yellow crystalline solid.  
Characterization agrees with that reported elsewhere (publication in writing).  1H NMR (400 MHz, CDCl3) 
δ 8.86 (d, J = 5.1 Hz, 1H), 7.84 (d, J = 5.1 Hz, 1H), 2.72 (s, 3H).  
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Di-(4-acetyl-2-(4-methylpiperazino)pyrimidine) trihydrobromide (8). A solution of 7 (0.18 g, 1.0 
mmol) in toluene (3 ml) was treated with N-methylpiperazine (0.55 mL, 5.0 mmol).  The solution was 
heated to 70°C and stirred for 1 day until starting material was no longer detected by TLC.  The solution 
was then evaporated to dryness under redeuced pressure and purified by chromatography 
(dichloromethane:methanol, 10:1) yielded the free base (0.170 g, 0.69 mmol, 70%) as a yellow oil.  1H 
NMR for the free base (400 MHz, CDCl3) δ 8.50 (d, J = 5.1 Hz, 1H) 7.03 (d, J = 5.1Hz, 1H), 3.91 (m, 4H), 
2.62 (s, 3H), 2.50 (m, 4H), 2.36 (s, 3H).  A hydrobromide salt. Anal. Calcd. for (C11H16N4O)2•3 HBr: C, 
38.67; H, 5.16; N, 16.40.  Found: C, 38.82; H, 5.05; N, 16.41. 
General procedure for compounds 9a-c[14]. A solution of 8 (0.12 g, 0.5 mmol) and sodium hydroxide 
(0.12 g, 3.0 mmol) dissolved in ethanol (10 mL) was treated with the appropriate hydroxylamine or 
hydrazine (5 mmol).  The solution was stirred for two hours then extracted into diethyl ether (3 X 20 
mL).  Purification by chromatography (dichloromethane:methanol, 6:1) yielded pyrimidine derivatives 
9a-c as yellow oils. 
Di-(1-(2-(4-methylpiperazino)-4-pyrimidinyl)ethanone oxime) trihydrobromide (9a). The free base was 
obtained in 76% yield.  1H NMR of the free base (400 MHz, CDCl3) δ 8.50 (d, J = 5.1 Hz, 1H) 7.03 (d, J = 5.1 
Hz, 1H), 3.91 (m, 4H), 2.62 (s, 3H), 2.50 (m, 4H), 2.36 (s, 3H); NOESY correlations observed between 
hydrogens bonded to adjacent piperazine carbons.  A hydrobromide salt: mp 249 °C (dec.).  Anal. Calcd. 
for C11H17N5O •2 HBr, ½ H2O: C, 32.53; H, 4.96; N, 17.24.  Found: C, 32.55; H, 4.77; N, 17.07. 
4-(1-Hydrazonoethyl)-2-(4-methylpiperazino)pyrimidine dihydrobromide (9b). The free base was 
obtained in 76% yield.  1H NMR of the free base (400 MHz, CDCl3) δ 8.23 (d, J = 5.1 Hz, 1H) 7.07 (d, J = 5.1 
Hz, 1H), 5.71 (s, 2H, -NH2), 3.88 (m, 4H), 2.49 (m, 4H), 2.35 (s, 3H), 2.15 (s, 3H).  A hydrobromide salt: mp 
207 °C (dec.). Anal. Calcd. for C11H18N6O •1.5 HBr, 1.5 H2O: C, 34.52; H, 5.93; N, 21.96.  Found: C, 34.64; 
H, 5.48; N, 21.51. 
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1-(2-(4-Methylpiperazino)-4-pyrimidinyl)ethanone O-ethyl oxime dihydrobromide (9c). The free base 
was obtained in 29% yield. 1H NMR of the free base (400 MHz, CDCl3) δ 8.26 (d, J = 5.1 Hz, 1H), 7.04 (d, J 
= 5.1 Hz, 1H), 4.27 (q, J = 7.0 Hz, 2H), 3.87 (m, 4H), 2.48 (m, 4H), 2.34 (s, 3H), 2.21 (s, 3H), 1.33 (t, J = 7.0 
Hz, 3H).  A hydrobromide salt.  Anal. Calcd for C13H21N5O •2 HBr, H2O: C, 35.23; H, 5.69; N, 15.80.  Found: 
C, 35.50; H, 5.52; N, 15.39. 
General procedure for compounds 10b-l. A solution of 3b (0.18 g, 1.0 mmol) and potassium carbonate 
(0.27 g, 2.0 mmol) in acetonitrile (5 mL) was treated with the appropriate 4-substituted piperazine (1.1 
mmol).  The solution was heated to 100 °C until starting material was no longer detected by TLC (5-24 
hours).  The solution was diluted with water (10 mL) and the product was extracted into diethyl ether (3 
X 20 mL).  The organic phase was dried over magnesium sulfate and concentrated before purification by 
chromatography (dichloromethane:methanol, 10:1). 
2-(4-Ethylpiperazino)-4-(3-furyl)pyrimidine dihydrobromide (10b). The free base was obtained in 61% 
yield as an oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.29 (d, J = 5.1 Hz, 1H), 8.07 (m, 1H), 7.48 (m, 
1H), 6.86 (m, 1H), 6.63 (d, J = 5.1 Hz, 1H), 3.91 (m, 4H), 2.53 (m , 4H), 2.49 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 
7.2 Hz, 3H).  A hydrobromide salt.  Anal. Calcd for C14H18N4O•2 HBr, ½ H2O: C, 39.18; H, 4.93; N, 13.06.  
Found: C, 39.29; H, 4.36; N, 12.81. 
4-(3-Furyl)-2-(4-propylpiperazino)pyrimidine dihydrobromide (10c). The free base was obtained in 39% 
yield as an oil.  1H NMR of the free base (400 MHz, CDCl3) δ  8.29 (d, J = 5.1 Hz, 1H), 8.06 (s, 1H), 7.48 (s, 
1H), 6.86 (s, 1H), 6.63 (d, J = 5.1 Hz, 1H), 3.90 (t, 4H), 2.52 (m, 4H), 2.36 (t, J = 7.4 Hz, 2H), 1.57 (m, 2H), 
0.94 (t, J = 7.4 Hz, 3H).  A hydrobromide salt:  mp 274 - 277 °C.  Anal. Calcd for C15H20N4O•2 HBr, H2O: C, 
39.84; H, 5.35; N, 12.39.  Found: C, 40.39; H, 4.84; N, 12.45. 
2-(4-Benzylpiperazino)-4-(3-furyl)pyrimidine dihydrobromide (10d). The free base was obtained in 73% 
yield as an oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.28 (d, J = 5.1 Hz, 1H), 8.05 (m, 1H), 7.47 (m, 
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1H), 7.31 (m, 5H), 6.85 (s, 1H), 6.62 (d, J = 5.1 Hz, 1H), 3.89 (m, 4H), 3.57 (s, 2H), 2.53 (m, 4H). A 
hydrobromide salt. Anal. Calcd for C19H20N4O•2 HBr, H2O: C, 45.62; H, 4.84; N, 11.20.  Found: C, 45.93; H, 
4.67; N, 11.11. 
Di-(4-(3-furyl)-2-(4-(4-methoxybenzyl)piperazino)pyrimidine) trihydrobromide (10e). The free base was 
obtained in 87% yield as a colorless oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.27 (d, J = 5.1 Hz, 
1H), 8.04 (m, 1H), 7.47 (m, 1H), 7.26 (m, 2H), 6.87 (m, 2H), 6.84 (m, 1H), 6.61 (d, J = 5.1 Hz, 1H), 3.87 (m, 
4H), 3.81 (s, 3H),  3.50 (s, 2H), 2.50 (m, 4H). 13C NMR of the free base (100 MHz, CDCl3) δ 161.8, 159.0, 
158.8, 158.0, 143.9, 143.0, 130.4, 130.0, 126.2, 113.7, 108.5, 105.6, 62.6, 55.3, 53.0, 43.7.  A 
hydrobromide salt: mp 195 °C (dec.).  Anal. Calcd for C20H22N4O2•1½ HBr: C, 50.92; H, 5.02; N, 11.88.  
Found: C, 50.82; H, 4.56; N, 11.89. 
4-(3-Furyl)-2-(4-(3-methoxybenzyl)piperazino)pyrimidine hydrobromide (10f). The free base was 
obtained in 40% yield.  1H NMR (400 MHz, CDCl3)  δ 8.27 (d, J = 5.1 Hz, 1H), 8.04 (m, 1H), 7.46 (t, J = 1.8 
Hz, 1H), 7.25 (m, 1H), 6.93 (m, 2H), 6.84 (m, 1H), 6.81 (m, 1H), 6.60 (d, J = 5.1 Hz, 1H), 3.88 (m, 4H), 3.81 
(s, 3H), 3.53 (s, 2H), 2.52 (m, 4H).  A hydrobromide salt: mp 245 - 247 °C (dec.).  Anal. Calcd for 
C20H22N4O2•HBr, ½ H2O: C, 54.55; H, 5.49; N, 12.72.  Found: C, 54.87; H, 5.04; N, 12.89. 
2-(4-(4-Chlorobenzyl)piperazino)-4-(3-furyl)pyrimidine dihydrobromide (10g). The free base was 
obtained in 36% yield as a colorless oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.28 (d, J = 5.1 Hz, 
1H), 8.05 (m, 1H), 7.47 (m, 1H), 7.28 (m, 4H), 6.84 (m, 1H), 6.62 (d, J = 5.1 Hz, 1H), 3.88 (m, 4H), 3.51 (s, 
2H), 2.50 (m, 4H). 13C NMR of the free base (100 MHz, CDCl3) δ 161.8, 159.0, 158.0, 143.9, 143.0, 136.6, 
132.8, 130.4, 128.4, 126.2, 108.5, 105.7, 62.4, 53.0, 43.7.  Mass spectroscopy (EI); calcd for 
C19H19
35ClN4O: 354, found: 354.  A hydrobromide salt: mp 231 °C (dec.). Anal. Calcd for C19H19ClN4O•2 
HBr: C, 44.17; H, 4.10; N, 10.84.  Found: C, 44.24; H, 3.80; N, 10.84. 
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2-(4-(3-Chlorobenzyl)piperazino)-4-(3-furyl)pyrimidine dihydrobromide (10h). The free base was 
obtained in 60% yield as a colorless oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.28 (d, J = 5.1 Hz, 
1H), 8.05 (m, 1H), 7.47 (t, J = 1.8Hz, 1H), 7.38 (s, 1H), 7.25 (m, 3H), 6.85 (m, 1H),6.62 (d, J = 5.1 Hz, 1H),  
3.89 (m, 4H), 3.53 (s, 2H), 2.52 (m, 4H). 13C NMR of the free base (100 MHz, CDCl3) δ 161.8, 159.0, 158.0, 
143.9, 143.0, 140.3, 134.2, 129.5, 129.1, 127.3, 127.2, 126.2, 108.5, 105.7, 62.6, 53.1, 43.7.  A 
hydrobromide salt: mp 257-259 °C. Anal. Calcd for C19H19ClN4O•2 HBr: C, 44.17; H, 4.10; N, 10.84.  
Found: C, 44.39; H, 3.83; N, 10.77. 
2-(4-Benzoylpiperazino)-4-(3-furyl)pyrimidine hydrobromide (10i). The free base was obtained in 33% 
yield as a yellow oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.31 (d, J=5.1 Hz, 1H), 8.06 (m, 1H), 
7.48 (m, 1H), 7.44 (m, 5H), 6.85 (m, 1H), 6.69 (d, J=5.1 Hz, 1H), 3.48-4.05 (broad m, 8H). 13C NMR of the 
free base (100 MHz, CDCl3) δ 170.6, 161.7, 159.2, 158.13, 144.0, 143.1, 135.8, 129.8, 128.6, 127.1, 126.0, 
108.5, 106.3, 44.0, 42.3. A hydrobromide salt: mp 221 °C (dec.). Anal. Calcd for C19H18N4O2•HBr, ½ H2O: 
C, 53.79; H, 4.75; N, 13.20.  Found: C, 53.97; H, 4.32; N, 13.15. 
2-(4-(4-tert-Butylbenzyl)piperazino)-4-(3-furyl)pyrimidine dihydrobromide (10j). The free base was 
obtained in 45% yield as an oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.27 (d, J = 5.1 Hz, 1H), 8.04 
(m, 1H), 7.46 (m, 1H), 7.38 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 6.84 (m, 1H), 6.61 (d, J = 5.1 Hz, 
1H), 3.88 (m, 4H), 3.53 (s, 2H), 2.52 (m, 4H), 1.33 (s, 9H).  13C NMR of the free base (100 MHz, CDCl3) δ 
161.8, 159.0, 158.0, 150.0, 143.9, 143.0, 134.9, 129.0, 126.3, 125.2, 108.5, 105.5, 62.9, 53.1, 43.8, 34.5, 
31.4. A hydrobromide salt: mp 235 - 237 °C (dec.). Anal. Calcd for C23H28N4O•2 HBr, H2O: C, 49.66; H, 
5.80; N, 10.07.  Found: C, 49.48; H, 5.23; N, 10.01. 
4-(3-Furyl)-2-(4-naphthylmethylpiperazino)pyrimidine dihydrobromide (10k). The free base was 
obtained in 22% yield. 1H NMR of the free base (400 MHz, CDCl3) δ 8.35 (d, J = 7.6 Hz, 1H), 8.27 (d, J = 5.1 
Hz, 1H), 8.04 (s, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.40-7.55 (m, 5H), 6.84 (s, 1H), 6.61 
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(d, J = 5.1 Hz, 1H), 3.95 (s, 2H), 3.87 (m, 4H), 2.59 (m, 4H). 13C NMR of the free base (100 MHz, CDCl3) δ 
161.8, 159.0, 158.0, 143.9, 143.0, 133.9 (2 signals), 132.6, 128.4, 128.0, 127.5, 126.2, 125.8, 125.7, 
125.1, 124.8, 105.5, 61.3, 53.3, 43.8. A hydrobromide salt. Anal. Calcd for C23H22N4O•2 HBr, H2O: C, 
50.20; H, 4.76; N, 10.18.  Found: C, 49.79; H, 4.47; N, 9.93. 
1,4-Bis(4-(3-furyl)-2-pyrimidinyl)piperazine dihydrobromide (10l). The free base was obtained in 16% 
yield as an oil.  1H NMR of the free base (400 MHz, CDCl3) δ 8.32 (d, J = 5.1 Hz, 2H), 8.10 (m, 2H), 7.50 (m, 
2H), 6.89 (m, 2H), 6.68 (d, J = 5.1 Hz, 2H), 3.98 (s, 8H).  13C NMR of the free base (100 MHz, CDCl3) δ 
161.9, 159.1, 158.1, 143.9, 143.1, 126.2, 108.5, 105.9, 43.7. A hydrobromide salt: mp: 270 °C (dec.).  
Anal. Calcd for C20H18N6O2•2 HBr, 3 H2O: C, 40.70; H, 4.44; N, 14.24.  Found: C, 40.58; H, 4.23; N, 14.07. 
General procedure for compounds 12a-f and 13a-f. Bromophenols 11a-e were commercially available.  
The established procedure was followed [11].  In summary, potassium hydroxide (0.7 g, 10 mmol) was 
dissolved in H2O (4 mL).  The solution was stirred during the sequential addition of DMSO (20 mL), the 
appropriate bromophenol 11 (8.6 mmol), and 2-bromo-1,1-diethoxyethane (1.4 mL, 9.3 mmol).  After 
complete addition, the mixture was heated under reflux for 1 day.  After cooling, the product was 
extracted into diethyl ether and washed with H2O and 5% NaOH.  The organic solution was then dried 
over MgSO4, filtered, and concentrated to yield 12a-e as colorless oils.  Compounds 12a-e were used 
without purification. A solution of polyphosphonic acid (20 g) in chlorobenzene (50 mL) was heated to 
reflux before the dropwise addition of 12a-e (33 mmol).  The solution was kept at reflux for 24 hours, 
resulting in a black solution containing a large amount of tar.  The product was decanted from the 
remaining solid, which was then washed with diethyl ether (2 X 20 mL).  The organic layer was then 
washed with aqueous sodium hydroxide (5%, 100 mL).  The organic layer was dried over magnesium 
sulfate and concentrated before purification by chromatography (hexanes) yielded benzofurans 13a-e as 
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colorless oils.  Compounds 12c, 12d and 13a were used in subsequent steps without isolation.  
Compounds which were isolated are characterized below. 
1-Bromo-3-(2,2-diethoxyethoxy)benzene (12a).This compound was obtained in 80% yield as a faintly 
brown oil.  Characterization agrees with that previously reported [96].  1H NMR (400 MHz, CDCl3) δ 1.26 
(t, 6H, 2 -CH3, J=7.0Hz), 3.68-3.83 (m, 4H, 2 -CH2), 4.05 (d, 2H, -CH2, J=5.2Hz), 4.88 (t, 1H, -CH, J=5.2Hz), 
6.88 (m, 2H, 2 -CH), 7.24 (m, 1H, -CH), 7.53 (m, 1H, -CH).  
4-Bromo-2-(2,2-diethoxy)toluene (12b). This compound was obtained in 83% yield. 1H NMR (400 MHz, 
CDCl3) δ 6.95-6.99 (m, 3H), 4.83-4.86 (t, J = 5.2 Hz, 1H), 3.97-3.99 (d, J = 5.2Hz, 2H), 3.63-3.80 (m, 4H), 
2.17 (s, 3H), 1.24-1.27 (t, J = 7.0 Hz, 6H).  13C NMR (100 MHz, CDCl3) δ 157.4, 131.6, 125.9, 123.6, 119.4, 
114.7, 100.5, 69.0, 62.8, 15.9, 15.4. High resolution ms: (ESI, positive ion mode): calc’d for C13H19O3
79Br, 
(M++ Na), 325.0415; found 325.0429. 
3-Bromo-4-(2,2-diethoxy)toluene (12e).  This compound was obtained in 97% yield as a light brown oil.  
Characterization agrees with that previously reported [96].  1H NMR (400 MHz, CDCl3) δ 1.25 (t, 6H, 2 -
CH3, J=7.0 Hz), 2.26 (s, 3H, -CH3), 3.65-3.84 (m, 4H, 2 -CH2), 4.02 (d, 2H, -CH2, J=5.2 Hz), 4.86 (t, 1H, -CH, 
J=5.2 Hz), 6.80 (d, 1H, -CH, J=8.2 Hz), 7.03 (dd, 1H, -CH, J=1.8, 8.2 Hz), 7.35 (dd, 1H, -CH, J=1.8 Hz).  13C 
NMR (100 MHz, CDCl3) δ 15.37, 20.18, 63.33, 70.39, 100.76, 111.96, 113.56, 128.84, 131.91, 133.74, 
152.98. 
 4-Bromo-7-methylbenzofuran (13b). This compound was obtained in 23% yield as a white solid: mp 34 
°C. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 2.0 Hz, 1H), 7.26-7.28 (d, J = 7.8 Hz, 1H), 6.94-6.96 (d, J = 7.8 
Hz, 1H), 6.78 (d, J = 2.0 Hz, 1H), 2.47 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 153.8, 145.1, 128.2, 126.1, 
125.7, 121.0, 111.1, 107.0, 14.8. 
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5-Bromobenzofuran (13c).  This compound was obtained in 28% yield as a clear oil.  Characterization 
agrees with that previously reported [140].  1H NMR (400 MHz, CDCl3) δ 6.72 (d, 1H, -CH, J=2.0Hz), 7.38 
(s, 1H, -CH), 7.62 (d, 1H, -CH, J=2.0 Hz), 7.73 (s, 1H, -CH).  
7-Bromobenzofuran (13d).  This compound was obtained in 31% yield as a colorless oil.  
Characterization agrees with that previously reported [96].  1H NMR (400 MHz, CDCl3) δ 6.85 (m, 1H, -
CH), 7.13 (m, 1H, -CH), 7.48 (m, 1H, -CH), 7.55, (m, 1H, -CH), 7.69, (m, 1H, -CH). 
7-Bromo-5-methylbenzofuran (13e).  This compound was obtained in 25% yield as a clear oil.  
Characterization agrees with that previously reported [141].  1H NMR (400 MHz, CDCl3) δ 2.42 (s, 3H, -
CH3), 6.75 (s, 1H, -CH), 7.29 (s, 1H, -CH), 7.31 (s, 1H, -CH), 7.64 (s, 1H, -CH).  
13C NMR (100 MHz, CDCl3) δ 
21.03, 103.54, 107.14, 120.32, 128.40, 128.66, 133.98, 145.68, 150.51. 
General procedure for compounds 14a-g. The published procedure for Buchwald-Hartwig amination 
was followed [15].  All substituted piperazines were commercially available. Briefly, in dry conditions a 
solution of the appropriate aryl halide 13 (1.0 mmol) in toluene (5 mL) was treated with a 4-substituted 
piperazine (1.2 mmol) in the presence of tert-butoxide (2.0 mmol) catalysts 
tris(dibenzylideneacetone)dipalladium(0) (0.01 mmol), and racemic 2,2'-bis(diphenylphosphino)-1,1'-
binaphthyl (0.01 mmol). The mixture was heated at reflux for 1 day before quenching with H2O.  After 
cooling, the product was extracted into diethyl ether (3 X 10 mL).  The organic layer was dried over 
MgSO4, filtered and concentrated under reduced pressure before purification 
(dichloromethane:methanol, 10:1) yielded substituted ayrlpiperazines 14. 
6-(4-Methylpiperazino)benzofuran hydrobromide (14a). This compound was obtained through a 
modification of the general procedure listed above.  As 13a was not able to be isolated from its 
constitutional isomer, the reaction was performed using a crude mixture of its isomers.  Workup and 
purification by flash chromatography using a mobile phase of dichloromethane:methanol (10:1) gave a 
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mixture of constitutional isomers.  This mixture was resolved by enrichment through crystallization.  To 
the isomeric mixture was added one drop of MeOH and diethyl ether (3 mL), followed by HBr (48%, 1 
drop).  To the solution was then added 5 mL ether and after several hours at room temperature, 14a 
precipitated as a white solid.  This procedure was repeated until the salt was isolated as determined by 
1H NMR in 38% yield: mp 206 °C.  1H NMR (400 MHz, DMSO) δ 9.6 (broad s, 1H), 7.84 (d, J = 2.0Hz, 1H), 
7.52 (d, J = 8.5Hz, 1H), 7.22 (s, 1H), 7.02 (dd, J = 2.0Hz, 8.5Hz, 1H), 6.83 (d, J = 1.4Hz, 1H), 3.4-3.6 (broad 
m, 2H), 3.8-4.0 (broad m, 2H), 3.1-3.3 (broad m, 2H), 2.9-3.1 (broad m, 2H), 2.87 (s, 3H).  Anal. Calcd for 
C13H16N2O • HBr: C, 52.54; H, 5.77; N, 9.43.  Found: C, 53.07; H, 5.92; N, 9.71. 
7-Methyl-4-(N-methylpiperazino)benzofuran dihydrobromide (14b). The free base was obtained in 
38% yield as a white crystalline solid: mp 62-64 °C. 1H NMR for the free base (400 MHz, CDCl3) δ 7.58 (d, 
J = 2.0 Hz, 1H), 6.99-7.01 (d, J = 7.8 Hz, 1H), 6.77 (d, J = 2.0 Hz, 1H), 6.62-6.64 (d, J = 7.8 Hz, 1H), 3.19-
3.22 (m, 4H), 2.64-2.67 (m, 4H), 2.46 (s, 3H), 2.39 (s, 3H). 13C NMR for the free base (100 MHz, CDCl3) δ 
154.9, 144.3, 143.3, 125.3, 119.9, 115.7, 109.8, 105.5, 55.4, 51.4, 46.2, 14.6.  High resolution ms (ESI, 
positive ion mode): calcd for C14H18N2O, (M
++H), m/z 231.1497; found m/z 231.1490. A hydrobromide 
salt: mp 263 - 265 °C. Anal. Calcd for C14H18N2O •2 HBr: C, 42.88; H, 5.14; N, 7.14.  Found: C, 42.76; H, 
5.20; N, 7.14. 
5-(4-Methylpiperazino)benzofuran hydrobromide (14c). The free base was obtained in 34% yield.  1H 
NMR for the free base (400 MHz, CDCl3) δ 7.56 (s, 1H), 7.39 (d, J = 9.0 Hz, 1H), 7.11 (s, 1H), 7.00 (d, J = 
9.0 Hz, 1H), 6.68 (s, 1H), 3.19 (m, 4H), 2.64 (m, 4H), 2.38 (s, 3H).  A hydrobromide salt. Anal. Calcd for 
C13H16N2O •HBr, ½ H2O: C, 50.99; H, 5.93; N, 9.15.  Found: C, 51.19; H, 5.93; N, 9.32. 
7-(N-Methylpiperazino)benzofuran dihydrobromide (14d). The free base was obtained in 39% yield and 
characterization matched that previously reported [98].  1H NMR for the free base (400 MHz, CDCl3) δ, 
7.60 (s, 1H), 7.12-7.22 (m, 2H), 6.74-6.79 (m, 2H), 3.38 (m, 4H), 2.68 (m, 4H), 2.39 (s, 3H).  High 
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resolution ms (ESI, positive ion mode): calcd for C13H16N2O, (M
++1), m/z 231.1497; found m/z 231.1490. 
A hydrobromide salt: mp 242 °C. Anal. Calcd for C13H16N2O •2 HBr, H2O: C, 39.42; H, 5.09; N, 7.07.  
Found: C, 39.62; H, 5.21; N, 6.79. 
1-Methyl-4-(5-methyl-7-benzofuryl)piperazine hydrobromide (14e). The free base was obtained in 
46% yield as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 2.39 (s, 3H, -CH3), 2.46 (s, 3H, -CH3), 2.64-2.67 
(m, 4H, 2 -CH2), 3.19-3.22 (m, 4H, 2 -CH2), 6.62-6.64 (d, 1H, -CH, J=7.8 Hz), 6.77 (d, 1H, -CH, J=2.0 Hz), 
6.99-7.01 (d, 1H, -CH, J=7.8 Hz), 7.58 (d, 1H, -CH, J=2.0 Hz).  13C NMR (100 MHz, CDCl3) δ 14.63, 46.20, 
51.36, 55.37, 105.48, 109.78, 115.71, 119.94, 125.30, 143.25, 144.32, 154.89.  High resolution ms (ESI, 
positive ion mode): calcd for C13H16N2O, (M
++1), m/z 231.1497; found m/z 231.1490 A hydrobromide 
salt: mp 212 - 213 °C (dec.).  EA (CHN) Calcd for C14H18N2O •2 HBr: C, 42.88; H, 5.14; N, 7.14.  Found: C, 
42.76; H, 5.20; N, 7.14. 
tert-Butyl 4-(5-methyl-7-benzofuranyl)piperazine-1-carboxylate (14f). The free base was obtained in 
51% yield as a light yellow glass.  1H NMR (400 MHz, CDCl3) δ 7.56 (d, 1H, -CH, J=1.6 Hz), 7.01 (s, 1H, -
CH), 6.67 (d, 1H, -CH, J=1.6 Hz), 6.57 (s, 1H, -CH), 3.66 (m, 4H, 2 -CH2) 3.26 (m, 4H, 2 -CH2),2.40 (s, 3H, -
CH3), 1.50 (s, 9H, 3 -CH3).  
13C NMR (100 MHz, CDCl3) δ 154.7, 145.3, 144.1, 136.7, 133.0, 128.7, 114.3, 
112.8, 106.7, 79.8, 49.8, 43.5, 28.4, 21.6.   
5-Methyl-(7-piperazino)benzofuran (14g). This compound was prepared according to the published 
procedure.  In summary, to a solution of 14f (1.3g, 4.1 mmol) in dichloromethane (5 mL) was added TFA 
(2.0 mL).  The mixture was stirred for several hours until the presence of starting material was no longer 
detected by TLC.  Purification by chromatography (dichloromethane:methanol, 10:1) gave 17 (0.78g, 3.6 
mmol, 88%) as a light yellow glass. Characterization matched that previously reported. 1H NMR (400 
MHz, CDCl3) δ 2.41 (s, 3H, -CH3), 3.43 (m, 4H, 2 -CH2), 3.57 (m, 4H, 2 -CH2), 6.58 (s, 1H, -CH), 6.69 (d, 1H, -
CH, J=2.0 Hz), 7.07 (s, 1H, -CH), 7.57 (d, 1H, -CH). 
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 (4-Bromo-1,1-dimethylbutyl)sulfonylbenzene (15). This compound was prepared according to the 
literature.  Briefly, a solution of isopropyl phenyl sulfide (0.50 g, 3.3 mmol) in dichloromethane (30 mL) 
was treated dropwise with a solution of m-chloroperoxybenzoic acid (2.4 g, 50% by wt, 7 mmol).  The 
mixture was stirred under mild heating (38 °C) and resulted in steady bubbling and a white precipitate.   
After complete addition, the reaction was quenched and washed with water.  Preparatory 
chromatography yielded [(1-methylethyl)sulfonyl]benzene in quantitative yield.  To a dry flask 
containing (1-methylethyl)sulfonylbenzene was added 5 mL anhydrous THF.  After cooling to -78 °C, n-
butyllithium (1.3 mL, 3.3 mmol) was added dropwise and stirred for 30 min before the addition of an 
excess of 1,3 dibromopropane (2.0 g, 10 mmol).  The mixture was then stirred and allowed to reach 0 °C 
before quenching with aqueous ammonium chloride.  The product was extracted into diethyl ether (2 X 
20 mL) and the extract was dried over magnesium sulfate and concentrated.  Purification on a 
chromatotron (hexanes:dichloromethane, 9:1) yielded 19 in 35% yield as a white solid: mp 69 - 70 °C. 
Characterization agrees with that previously reported. [83]  1H NMR (400 MHz, CDCl3) δ 1.31 (s, 6H, 2 -
CH3), 1.83-1.87 (m, 2H, -CH2), 1.95-2.00 (m, 2H, -CH2), 3.40 (t, 2H, -CH2, J=6.6 Hz), 7.57 (t, 2H, 2 -CH, J=7.6 
Hz), 7.67 (t, 1H, -CH, J=7.6 Hz), 7.88 (d, 2H, 2 -CH2, J=7.6 Hz).
 
6-Bromo-N-(4-cyanophenyl)methylhexanamide (16). The published procedure was followed [84]. 
Briefly, a solution of 4-(aminomethyl)benzonitrile (2.64 g, 20 mmol) in aqueous sodium hydroxide (0.5 
M, 50 mL) was stirred vigorously and treated dropwise with 6-bromohexanoyl chloride (5.0 g, 23.4 
mmol).  The pH of the reaction was maintained near 9 with aqueous sodium hydroxide (0.5 M, 100 mL). 
After 30 min, the resulting white precipitant was extracted with dichloromethane.  The resulting residue 
was recrystallized from diethyl ether to yield 16 as a white semisolid.  Characterization agrees with that 
previously reported. 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 5.89 
(broad s, 1H), 4.50 (d, J = 6.0 Hz, 2H), 3.42 (t, J = 6.6 Hz, 2H), 2.27 (t, J = 7.4 Hz, 2H), 1.88 (m, 2H), 1.71 
(m, 2H), 1.50 (m, 2H).  
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General procedure for compounds 17a-b. A solution of the appropriate bromide (0.25 mmol) in 
acetonitrile (5 mL) was treated with the appropriate amine (0.25 mmol).  To this mixture was added 
K2CO3 (0.50 mmol).  The mixture was heated under reflux for 1-3 days, until the starting materials were 
no longer detected by TLC.  Water (10 mL) was added to the mixture and the products were extracted 
into diethyl ether.  The extract was dried over magnesium sulfate, filtered and concentrated under 
reduced pressure.  Purification on a chromatotron (dichloromethane:methanol, 10:1) yielded 17a-b.  
Characterization of these compounds follows. 
1-[4-(Benzenesulfonyl)-4-methylpentyl]-4-(5-methyl-7-benzofuranyl)piperazine (17a). The free base 
was obtained in 30% yield as a faintly yellow oil.  1H NMR (400 MHz, CDCl3) δ 1.32 (s, 6H), 1.64 (m, 2H), 
1.76 (m, 2H), 2.41 (m, 5H), 2.68 (m, 4H), 3.33 (m, 4H), 6.56 (m, 1H), 6.66 (m, 1H), 6.99, (m, 1H), 7.56 (m, 
3H), 7.66 (t, J = 7.4 Hz, 1H), 7.89 (d, J=7.4 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 145.3, 144.0, 136.9, 
135.6, 133.5, 133.0, 130.6, 128.7, 128.6, 113.9, 112.6, 106.6, 62.9, 58.7, 53.4, 49.8, 32.8, 21.7, 21.5, 
20.9.  
N-(4-Cyanobenzyl)-6-(4-(5-methyl-7-benzofuranyl)piperazino)hexanamide (17b).  The free base was 
obtained in 28% yield.  1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 7.8 Hz, 2H), 7.56 (s, 1H), 7.38 (d, J = 7.8 
Hz, 2H), 7.00 (s, 1H), 6.67 (m, 1H), 6.56 (m, 1H), 6.16 (broad s, 1H), 4.49 (d, J = 5.8 Hz, 2H),  3.38 (m, 4H), 
2.75 (m, 4H), 2.49 (t, J = 7.6 Hz), 2.40 (s, 3H), 2.28 (t, J = 7.4 Hz), 1.72 (m, 2H), 1.62 (m, 2H), 1.40 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 173.1, 145.2, 144.1 (2 signals), 136.6, 133.1, 132.4, 128.6, 128.2, 118.7, 
114.1, 112.6, 111.2, 106.7, 58.3, 53.2, 49.4, 43.0, 36.3, 26.9, 26.1, 25.4, 21.7. High resolution ms: (ESI, 
positive ion mode): calcd for C27H32N4O2, (M
++1), m/z 445.2604; found m/z 445.2591. 
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APPENDICES 
A. List of abbreviations 
5-HT - 5-hydroxytryptamine 
ADD - attention deficit disorder 
AR - aromatic 
cAMP - cyclic adenosine monophosphate 
cDNA - circular DNA 
CNS - central nervous system 
CoMFA - comparative molecular field analysis 
CoMSIA - comparative molecular similarity indices analysis 
DDQ - 2,3-dichloro-5,6-dicyanoquinone 
EDTA - ethylenediaminetetraacetic acid 
ERK - extracellularly regulated kinase 
GABA - gamma-aminobutyric acid 
GPCR - G-protein coupled receptor 
GI - gastrointestinal 
HBA - hydrogen bond acceptor 
HEK - human embryonic kidney 
HTS - high throughput screening 
HYD - hydrophobic 
IL - intracellular loop 
LOO - leave-one-out 
LSD - lysergic acid diethylamide 
MAO - monoamine oxidase 
MAOI - monoamine oxidase inhibitor 
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mRNA - messenger RNA 
N - number of principal components 
OCD - obsessive compulsive disorder 
PA - protonated amine 
PLS - partial least squares 
PMAT - plasma membrane monoamine transporter 
PRESS - predicted residual sum of squares 
QSAR - quantitative structure-activity relationship 
RMS - root mean square 
SEM - standard error of measurement 
SERT - serotonin transporter 
SSRI - selective serotonin reuptake inhibitor 
THF - tetrahydrofuran 
TLC - thin layer chromatography 
TM - transmembrane 
TPH - tryptophan hydroxylase 
B. Glossary 
agonist  - A compound which upon binding to a receptor causes activity identical 
to when the receptor is bound with the natural ligand 
antagonist - A compound which upon binding to a receptor blocks activity identical 
to when the receptor is bound with the natural ligand 
bioavailability - A measure of the percentage of a dosage which enters systemic 
circulation.  Considerations relating to bioavailability include metabolism and absorption into 
the bloodstream. 
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central nervous system - Encompasses all of the brain and spinal cord 
circadian pacemaker - Refers to the structures which maintain daily rhythms such as 
feeding and sleeping 
docking - In this case, docking refers to molecular modeling methods which can 
be used to predict the binding mode of ligands.  Docking studies find the best fit for known 
ligands within a binding site, according to their minimized interactions with the receptor. 
dyspepsia - A loosely defined stomach ailment similar to an upset stomach or 
indigestion. 
enteric  - Pertaining to the intestines. 
enzyme - A protein which catalyzes a chemical reaction.  
forebrain structures - refers to structures implicated in higher order thought 
processes 
gastrointestinal - Pertaining to the entire system which is used to extract 
nutrients from ingested food. 
G-protein - Guanine binding proteins.  These proteins are most commonly seen 
with G-protein coupled receptors and use the altering phosphorylation states of GTP as a step in 
signal transduction. 
higher order (protein) structure - The complex three-dimensional folding patterns 
of proteins which form common structures, such as alpha helices. 
inhibitor - A compound which blocks the activity of a specific protein upon binding. 
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kinase  - An enzyme which transfers a phosphate group to a specific compound.   
neuronal - Pertaining to the cells (neurons) which regulate the release and 
reuptake of neurotransmitters for the purpose of signal transmission between nerve cells. 
pharmacological - Relating to a the actions of biological systems on a specific 
compound.  
pharmacophore  - A map of regions which are necessary for a compound 
to bind to a receptor.  A complete pharmacophore will include all necessary regions for binding 
and describe the nature of those interactions. 
physiological  - Referring to the biological purpose of a receptor as it relates to 
the processes it affects within the body. 
primary sequence - The order of amino acid residues in a protein. 
principal component - An algebraic matrix which represents compiled information 
about ligand structure for QSAR analysis. 
raphe nuclei  - Portion of the brain, near the brainstem, which houses the 
majority of serotonergic neurons. 
selectivity  - The ability of a ligand to bind only one (or few) 5-HT receptor 
subtypes and other monoamine receptors. 
sequence homology - A measure of the similarity between the sequence of residues in 
two different proteins. 
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signal transduction - Describes the event of intracellular changes being effected by 
an extracellular signal, such as the presence of a neurotransmitter. 
splice variants - Refers to proteins which are encoded from the same DNA sequence, yet 
have different sequences.  In the case of the 5-HT7 receptor, splice variants exist in which the 
protein sequence is truncated. 
synapse  - The space between neurons where signaling takes place.  The 
presence of neurotransmitters in this gap is essential to cell signaling. 
ternary complex model  - This model assumes a direct relationship between the  
the differences in dissociation constants of two ligands with respect to a receptor.  This is one 
way to determine the affinity of novel compounds to a receptor site. 
vasoconstrictor  - A compound which causes the blood vessels to become more 
narrow, due to constriction. 
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